ОСНОВНЫЕ ПРЕДИКТОРЫ, СПОСОБСТВУЮЩИЕ РАЗВИТИЮ КАРДИОВАСКУЛЯРНЫХ ОСЛОЖНЕНИЙ, У ВОЕННОСЛУЖАЩИХ С ВНУТРИБРЮШНОЙ ГИПЕРТЕНЗИЕЙ ПРИ ОСТРОЙ АБДОМИНАЛЬНОЙ ПАТОЛОГИИ

Θεματικοί όροι: внутрибрюшная гипертензия, кардиоваскулярные осложнения, острая абдоминальная патология, военнослужащие, сердечная недостаточность, предикторы риска

ОСНОВНЫЕ ПРЕДИКТОРЫ, СПОСОБСТВУЮЩИЕ РАЗВИТИЮ КАРДИОВАСКУЛЯРНЫХ ОСЛОЖНЕНИЙ, У ВОЕННОСЛУЖАЩИХ С ВНУТРИБРЮШНОЙ ГИПЕРТЕНЗИЕЙ ПРИ ОСТРОЙ АБДОМИНАЛЬНОЙ ПАТОЛОГИИ

Θεματικοί όροι: внутрибрюшная гипертензия, кардиоваскулярные осложнения, острая абдоминальная патология, военнослужащие, сердечная недостаточность, предикторы риска

САХАРНЫЙ ДИАБЕТ II ТИПА: ПРИЧИНЫ, СИМПТОМЫ И СОВРЕМЕННЫЕ ПОДХОДЫ К ЛЕЧЕНИЮ

Θεματικοί όροι: lifestyle, диабетическая невропатия, cardiovascular complications, управление диабетом, prediabetes, сахарный диабет 2 типа, diabetes management, кардиоваскулярные осложнения, медикаментозная терапия, лечение диабета, insulin resistance, предиабет, metabolic disorders, мониторинг глюкозы, диабетическая нефропатия, diabetes treatment, diabetic nephropathy, diabetes complications, гипергликемия, диабетическая ретинопатия, diabetic neuropathy, drug therapy, diabetic retinopathy, glucose monitoring, образ жизни, инсулинорезистентность, type 2 diabetes, hyperglycemia, метаболические нарушения, осложнения диабета

ПРОБЛЕМЫ КАРДИОТОКСИЧНОСТИ У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ НА ЭТАПЕ ПРОВЕДЕНИЯ ХИМИОЛУЧЕВОЙ ТЕРАПИИ

Συγγραφείς: Ирина Владиславовна Вологдина, Разифа Мидхатовна Жабина, Дмитрий Николаевич Майстренко, Виктор Николаевич Федорец, Лариса Анатольевна Красильникова

Πηγή: University Therapeutic Journal, Vol 3, Iss 1 (2021)

Θεματικοί όροι: противораковая терапия, факторы риска, кардиоваскулярные осложнения, кардиотоксичность, Medicine

Περιγραφή αρχείου: electronic resource

Relation: http://ojs3.gpmu.org/index.php/Un-ther-journal/article/view/2601; https://doaj.org/toc/2713-1912; https://doaj.org/toc/2713-1920

Σύνδεσμος πρόσβασης: https://doaj.org/article/1e5918437b4d4459b7fe57897de961ef

ПРОБЛЕМЫ КАРДИОТОКСИЧНОСТИ У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ НА ЭТАПЕ ПРОВЕДЕНИЯ ХИМИОЛУЧЕВОЙ ТЕРАПИИ

Συγγραφείς: Разифа Мидхатовна Жабина, Виктор Николаевич Федорец

Πηγή: University Therapeutic Journal, Vol 3, Iss 1 (2021)

Θεματικοί όροι: противораковая терапия, факторы риска, кардиоваскулярные осложнения, кардиотоксичность, Medicine

Relation: http://ojs3.gpmu.org/index.php/Un-ther-journal/article/view/2601; https://doaj.org/toc/2713-1912; https://doaj.org/toc/2713-1920; https://doaj.org/article/1e5918437b4d4459b7fe57897de961ef

Διαθεσιμότητα: https://doaj.org/article/1e5918437b4d4459b7fe57897de961ef

ПРОБЛЕМЫ КАРДИОТОКСИЧНОСТИ У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ НА ЭТАПЕ ПРОВЕДЕНИЯ ХИМИОЛУЧЕВОЙ ТЕРАПИИ

Πηγή: University Therapeutic Journal, Vol 3, Iss 1 (2021)

Θεματικοί όροι: противораковая терапия, кардиоваскулярные осложнения, Medicine, факторы риска, кардиотоксичность

Σύνδεσμος πρόσβασης: https://doaj.org/article/1e5918437b4d4459b7fe57897de961ef

METABOLIC FACTORS OF CARDIOVASCULAR RISK IN PATIENTS WITH DIABETIC NEPHROPATHY WHO UNDERGO PROGRAMMED HEMODYALISIS ; МЕТАБОЛИЧЕСКИЕ ФАКТОРЫ СЕРДЕЧНО-СОСУДИСТОГО РИСКА У ПАЦИЕНТОВ С ДИАБЕТИЧЕСКОЙ НЕФРОПАТИЕЙ НА ПРОГРАММНОМ ГЕМОДИАЛИЗЕ ; МЕТАБОЛІЧНІ ФАКТОРИ СЕРЦЕВО-СУДИННОГО РИЗИКУ В ПАЦІЄНТІВ ІЗ ДІАБЕТИЧНОЮ НЕФРОПАТІЄЮ НА ПРОГРАМНОМУ ГЕМОДІАЛІЗІ

Συγγραφείς: Susla, O. B., Litovkina, Z. I.

Πηγή: Bulletin of Scientific Research; No. 4 (2018); 55-60 ; Вестник научных исследований; № 4 (2018); 55-60 ; Вісник наукових досліджень; № 4 (2018); 55-60 ; 2415-8798 ; 1681-276X ; 10.11603/2415-8798.2018.4

Θεματικοί όροι: diabetic nephropathy, hemodialysis, cardiovascular complications, risk factors, magnesium deficiency, dyslipidemia, диабетическая нефропатия, гемодиализ, кардиоваскулярные осложнения, факторы риска, дефицит магния, дислипидемия, діабетична нефропатія, гемодіаліз, кардіоваскулярні ускладнення, фактори ризику, дефіцит магнію, дисліпідемія

Περιγραφή αρχείου: application/pdf

Relation: https://ojs.tdmu.edu.ua/index.php/visnyk-nauk-dos/article/view/9813/9464; https://repository.tdmu.edu.ua//handle/123456789/12771

Διαθεσιμότητα: https://repository.tdmu.edu.ua//handle/123456789/12771
https://ojs.tdmu.edu.ua/index.php/visnyk-nauk-dos/article/view/9813
https://doi.org/10.11603/2415-8798.2018.4.9813

The therapeutic potential of etoricoxib in clinical practice ; Терапевтический потенциал эторикоксиба в клинической практике

Συγγραφείς: A. E. Karateev, А. Е. Каратеев

Πηγή: Modern Rheumatology Journal; Том 14, № 1 (2020); 108-117 ; Современная ревматология; Том 14, № 1 (2020); 108-117 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2020-1

Θεματικοί όροι: кардиоваскулярные осложнения, etoricoxib, efficacy, safety, gastrointestinal tract, cardiovascular complications, эторикоксиб, эффективность, безопасность, желудочно-кишечный тракт

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1001/960; Van Hecke O, Torrance N, Smith BH. Chronic pain epidemiology and its clinical relevance. Br J Anaesth. 2013 Jul;111(1):13-8. doi:10.1093/bja/aet123; Lestoquoy AS, Laird LD, Mitchell S, et al. Living with chronic pain: Evaluating patient experiences with a medical group visit focused on mindfulness and non-pharmacological strategies. Complement Ther Med. 2017 Dec;35:33-8. doi:10.1016/j.ctim.2017.09.002. Epub 2017 Sep 12.; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 446 с. ISBN 978-5-9704-4261-6; GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic anlysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-858. doi:10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.; Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009–2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1688-94. doi:10.1002/acr.22890; Deyo R, Mirza S, Turner J, Martin B. Overtreating chronic back pain: time to back off? J Am Board Fam Med. 2009;22(1):62-8. doi:10.3122/jabfm.2009.01.080102; Nagakura Y. The need for fundamental reforms in the pain research field to develop innovative drugs. Expert Opin Drug Discov. 2017 Jan;12(1):39-46. doi:10.1080/17460441.2017.1261108. Epub 2016 Nov 22.; Peppin JF, Cheatle MD, Kirsh KL, McCarberg BH. The complexity model: a novel approach to improve chronic pain care. Pain Med. 2015 Apr;16(4):653-66. doi:10.1111/pme.12621. Epub 2015 Mar 6.; Conaghan PG, Peloso PM, Everett SV, et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. Rheumatology (Oxford). 2015 Feb;54(2): 270-7. doi:10.1093/rheumatology/keu332. Epub 2014 Aug 23.; Picavet HSJ, Monique Verschuren WM, Groot L, et al. Pain over the adult life course: 15-year pain trajectories – The Doetinchem Cohort Study. Eur J Pain. 2019 Oct;23(9): 1723-32. doi:10.1002/ejp.1450. Epub 2019 Jul 25.; Bastick AN, Wesseling J, Damen J, et al. Defining knee pain trajectories in early symptomatic knee osteoarthritis in primary care: 5-year results from a nationwide prospective cohort study (CHECK). Br J Gen Pract. 2016 Jan;66(642):e32-9. doi:10.3399/bjgp15X688129. Epub 2015 Dec 6.; Fornasari D. Pain mechanisms in patients with chronic pain. Clin Drug Investig. 2012 Feb;32 Suppl 1:45-52. doi:10.2165/11630070-000000000-00000; Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018 Feb;22(2): 216-41. doi:10.1002/ejp.1140; Vardeh D, Mannion RJ, Woolf CJ. Toward a mechanism-based approach to pain diagnosis. J Pain. 2016 Sep;17(9 Suppl): T50-69. doi:10.1016/j.jpain.2016.03.001; Salaffi F, Giacobazzi G, Di Carlo M. Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets – A focus on the JAK-STAT pathway. Pain Res Manag. 2018 Feb 7;2018:8564215. doi:10.1155/2018/8564215. eCollection 2018.; Conaghan PG, Cook AD, Hamilton JA, Tak PP. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat Rev Rheumatol. 2019 Jun;15(6):355-63. doi:10.1038/s41584-019-0221-y; Каратеев АЕ, Насонов ЕЛ, Ивашкин ВТ и др.; Ассоциация ревматологов России, Российское общество по изучению боли, Российская гастроэнтерологическая ассоциация, Российское научное медицинское общество терапевтов, Ассоциация травматологов-ортопедов России, Российская ассоциация паллиативной медицины. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56 Прил. 1:1-29. doi:10.14412/1995-4484-2018-1-29; Kawahara K, Hohjoh H, Inazumi T, et al. Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. Biochim Biophys Acta. 2015 Apr;1851(4): 414-21. doi:10.1016/j.bbalip.2014.07.008. Epub 2014 Jul 17.; Grö sch S, Niederberger E, Geisslinger G. Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain. Expert Opin Investig Drugs. 2017 Jan;26(1):51-61. doi:10.1080/13543784.2017.1260544. Epub 2016 Nov 20.; Salvado MD, Alfranca A, Haeggström JZ, Redondo JM. Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2. Trends Mol Med. 2012 Apr;18(4):233-43. doi:10.1016/j.molmed.2012.02.002. Epub 2012 Mar 17.; Nadda N, Vaish V, Setia S, Sanyal SN. Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer. Biomed Pharmacother. 2012 Sep;66(6):474-83. doi:10.1016/j.biopha.2012.04.002. Epub 2012 May 10.; Kim HS, Kim T, Kim MK, et al. Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia. J Cancer Prev. 2013 Jun;18(2):123-34. doi:10.15430/JCP. 2013.18.2.123; Tanwar L, Piplani H, Sanyal S. Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochlorideinduced colon carcinogenesis. Asian Pac J Cancer Prev. 2010;11(5):1329-33.; Dong X, Hu Y, Jing L, Chen J. Role of phosphorylated extracellular signal-regulated kinase, calcitonin gene-related peptide and cyclooxygenase-2 in experimental rat models of migraine. Mol Med Rep. 2015 Aug;12(2): 1803-9. doi:10.3892/mmr.2015.3616. Epub 2015 Apr 15.; Eisenach JC, Curry R, Tong C, et al. Effects of intrathecal ketorolac on human experimental pain. Anesthesiology. 2010 May; 112(5):1216-24. doi:10.1097/ALN. 0b013e3181d94d8b; Jakubowski M, Levy D, Kainz V, et al. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience. 2007 Aug 24;148(2): 573-83. doi:10.1016/j.neuroscience.2007.04.064. Epub 2007 Jul 25.; Martina S, Vesta K, Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005;39(5):854-62. doi:10.1345/aph.1E543; Malmstrom K, Sapre A, Couglin H, et al. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. Clin Ther. 2004 May; 26(5):667-79. doi:10.1016/S0149-2918(04) 90067-7; Kwiatkowska B, Majdan M, Mastalerz-Migas A, et al. Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. Reumatologia. 2017;55(6): 290-7. doi:10.5114/reum.2017.72626. Epub 2017 Dec 30.; Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015 Sep 28;(9):CD008659. doi:10.1002/14651858.CD008659.pub3; Moore RA, Straube S, Paine J, et al. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain. 2011 May; 152(5):982-9. doi:10.1016/j.pain.2010.11.030; Isola G, Matarese G, Alibrandi A, et al. Comparison of effectiveness of etoricoxib and diclofenac on pain and perioperative sequelae after surgical avulsion of mandibular third molars: A randomized, controlled, clinical trial. Clin J Pain. 2019 Nov;35(11):908-15. doi:10.1097/AJP.0000000000000748; Zhang S, Zhang Y, Liu P, et al. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol. 2016 Jan;35(1):151-8. doi:10.1007/s10067- 015-2991-1. Epub 2015 Jun 24.; Lin TM, Chi JE, Chang CC, Kang YN. Do etoricoxib and indometacin have similar effects and safety for gouty arthritis? A metaanalysis of randomized controlled trials. J Pain Res. 2018 Dec 19;12:83-91. doi:10.2147/JPR.S186004. eCollection 2019.; Bickham K, Kivitz AJ, Mehta A, et al. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of rheumatoid arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016 Aug 8;17:331. doi:10.1186/s12891-016-1170-0; Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal antiinflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016 Jun;75(6): 1152-60. doi:10.1136/annrheumdis-2015-207677. Epub 2015 Aug 6.; Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal antiinflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016 May 21; 387(10033):2093-105. doi:10.1016/S0140-6736(16)30002-2; Jung SY, Jang EJ, Nam SW, et al. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol. 2018 Nov;28(6):1021-8. doi:10.1080/14397595.2018.1439694. Epub 2018 Mar 1.; Zacher J, Feldman D, Gerli R, et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin. 2003;19(8):725-36. doi:10.1185/030079903125002469; Reginster J, Malmstrom K, Mehta A, et al. Evalution of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007;66(7): 945-51. doi:10.1136/ard.2006.059162; Давыдов ОС. Периферические и центральные механизмы перехода острой боли в хроническую и возможная роль ингибирования ЦОГ 2 в предотвращении хронизации болевого синдрома. Неврология, нейропсихиатрия, психосоматика. 2016;8(2):10-6. doi:10.14412/2074-2711- 2016-2-10-16; Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017;25(11):1781-91. doi:10.1016/j.joca.2017.07.009; Ramey D, Watson D, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005; 21(5):715-22. doi:10.1185/030079905X43686; Hunt R, Harper S, Watson D, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol. 2003;98(8): 1725-33. doi:10.1111/j.1572-0241.2003.07598.x; Watson D, Bolognese J, Yu C, et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin. 2004;20(12):1899-908. doi:10.1185/030079904X12681; Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One. 2018 Jan 10; 13(1):e0190798. doi:10.1371/journal.pone.0190798. eCollection 2018.; Каратеев АЕ, Погожева ЕЮ, Филатова ЕС, Амирджанова ВН. Эндоскопическая картина верхних отделов желудочнокишечного тракта на фоне приема различных нестероидных противовоспалительных препаратов. Клиническая фармакология и терапия. 2018;27(4):40-5.; Curtis S, Ko A, Bolognese J, et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Curr Med Res Opin. 2006;22(12):2365-74. doi:10.1185/030079906X148238; Cannon C, Sean P Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368:1771-81. doi:10.1016/S0140-6736(06)69666-9; Lin H, Cheng T, Wang J, et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis. 2010;13(2):144-50. doi:10.1111/j.1756-185X.2010.01468.x; Каратеев АЕ. Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы. Современная ревматология. 2018;12(2): 64-72. doi:10.14412/1996-7012-2018-2-64-72; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Lancet. 2013 Aug 31;382(9894):769-79. doi:10.1016/S0140-6736(13)60900-9; Kristensen LE, Jakobsen AK, Askling J, et al. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2015 Aug;67(8): 1137-49. doi:10.1002/acr.22555; Zingler G, Hermann B, Fischer T, Herdegen T. Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks. Exp Rev Clin Pharmacol. 2016 Sep 8:1-14.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1001
https://doi.org/10.14412/1996-7012-2020-1-108-117

The place of aceclofenac in the preparation of patients with rheumatic diseases for joint surgery ; Место ацеклофенака в подготовке больных с ревматическими заболеваниями к операциям на суставах

Συγγραφείς: V. N. Amirdzhanova, A. E. Karateev, В. Н. Амирджанова, А. Е. Каратеев

Συνεισφορές: Публикация статьи поддержана ООО «Гедеон Рихтер».

Πηγή: Modern Rheumatology Journal; Том 13, № 4 (2019); 124-129 ; Современная ревматология; Том 13, № 4 (2019); 124-129 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2019-4

Θεματικοί όροι: низкие дозы ацетилсалициловой кислоты, aceclofenac, preoperative preparation, rheumatic diseases, gastrointestinal and cardiovascular complications, low-dose acetylsalicylic acid, ацеклофенак, предоперационная подготовка, ревматические заболевания, желудочно-кишечные и кардиоваскулярные осложнения

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/970/931; Яхно НН, Кукушкин МЛ, редакторы. Боль (практическое руководство для врачей). Москва: Издательство РАМН; 2012. 512 c.; Carpintero P, Caeiro JR, Carpintero R, et al. Complications of hip fractures: A review. World J Orthop. 2014 Sep 18; 5(4):402-11. doi:10.5312/wjo.v5.i4.402. eCollection 2014.; Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-24. doi: 10. 14412/1996-7012-2015-1-4-23; Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis - an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015 Mar 19; 13: 55. doi:10.1186/s12916-015-0285-8.; Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013;16(5):821-47.; Lemmel E, Leeb B, De Bast J, Aslanidis S. Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. Curr Med Res Opin. 2002;18(3):146-53.; Peris F, Bird H, Serni U, et al. Treatment compliance and safety of aceclofenac versus standard NSAIDs in patients with common arthritic disorders: a metaanalysis. Eur J Rheumatol Inflamm.1996;(16):37-45.; Willoughby D, Moore A, Colville-Nash P. COX-1, COX-2 and COX-3 and the future treatment of chronic inflammatory disease. Lancet. 2000 Feb 19;355(9204):646-8.; Saraf S. Aceclofenac: A Potent NonSteroidal Anti-Inflammatory Drug. In Latest Reviews 2006; 4(3):119-24.; Hinz B, Rau T, Augel D, et al. Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35.; Насонова ВА, Каратеев АЕ. Симптоматическая терапия боли при ревматических заболеваниях: место ацеклофенака. Современная ревматология. 2009;3(3): 58-65. doi:10.14412/1996-7012-2009-560; Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis. Eur J Rheumatol. 2017 Mar;4(1):11-18. doi:10.5152/eurjrheum.2017.160080. Epub 2017 Mar 1.; Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78.; Presser Lima PV, Fontanella V. Analgesic efficacy of aceclofenac after surgical extraction of impacted lower third molars. Int J Oral Maxillofac Surg. 2006 Jun;35(6):518-21.; Насонов ЕЛ Специфические ингибиторы ЦОГ-2: решенные и нерешенные проблемы. Клиническая фармакология и терапия. 2000;(1):57-64.; Vane J, Botting R. Mechanism of action in nonsteroidal anti-inflammatori drugs. Am J Med. 1998 Mar 30;104(3A):2S-8S; discussion 21S-22S.; Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi:10.2165/11633470-000000000-00000.; Henrotin Y, De Leval X, Mathy-Hartet M, et al. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res. 2001 Aug;50(8):391-9.; Huskisson E, Irani M, Murray F. A large prospective open-label, multicentre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Europ J Rheumatol Inflamm. 2000; 7(1):1-7.; Lanas A, Garsia-Rodriguez L, Arroyo M, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-steroidal nonaspirin NSAID, aspirin, and combinations. Gut. 2006 Dec;55(12):1731-8. Epub 2006 May 10.; Laporte J, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004;27(6):411-20.; Llorente Melero MJ, Tenias Burillo JM, Zaragoza Marcet A. Comparative incidence of upper gastrointestinal bleeding associated with individual nonsteroidal anti-inflammatory drugs. Rev Esp Enferm Dig. 2002 Jan; 94(1):7-18.; Raber A, Heras J, Costa J, et al. Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom. Ther Clin Risk Manag. 2007 Jun;3(2):225-30.; Каратеев АЕ. Результаты клинического исследования АЭРОПЛАН (анализ эффективности и риска осложнений при лечении артрита ацеклофенаком и нимесулидом). Consilium Medicum. 2013;15(2): 48-53.; Каратеев АЕ. Ацеклофенак в ревматологии: «золотая середина». Современная ревматология. 2013;7(2):88-94. doi:10.14412/1996-7012-2013-2389; Huskisson EC. Aceclofenac: Ace or just another Jack? Europ J Rheum Inform. 1996; 16(1):1-2.; Helin-Salmivaara A, Virtanen A, Veslainen R, et al. NSAID use and the risk of hospitalisation for first myocardial infarction in the general population: a national casecontrol study from Finland. Eur Heart J. 2006 Jul;27(14):1657-63. Epub 2006 May 26.; Wood SG, Fitzpatrik K, et al. Pharmacokinetics and metabolism a new NSAID/analgesic aceclofenac in man. Pharm Res. 1990;7(9):212.; Лила АМ. Применение препарата Аэртал (ацеклофенак) в клинической практике. Русский медицинский журнал. 2009;17(4):291-4.; Лила АМ. Применение Аэртала в ревматологической практике. Справочник поликлинического врача. 2010;(8):47-9.; Насонова ВА. Ацеклофенак – безопасность и эффективность. Русский медицинский журнал. 2003;11(5):3-6.; Singh G, Graham D, Wang H, et al. Concominant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some nonselective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2006;65(Suppl. II):61.; Ашихмин ЯИ, Драпкина ОМ. Лечение болевого синдрома с позиции эффективности и безопасности. Эффективная фармакотерапия. Ревматология. Травматология. Ортопедия. 2011;(1):38-43.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/970
https://doi.org/10.14412/1996-7012-2019-4-124-129

Pro-inflammatory cytokines in patients with chronic kidney disease: interleukin-6 in focus ; Провоспалительные цитокины у больны х с хронической болезнью почек: в фокусе интерлейкин-6

Συγγραφείς: I. T. Murkamilov, K. A. Aitbae, V. V. Fomin, Zh. A. Murkamilova, I. S. Sabirov, Z. R. Rayimzhanov, N. A. Redzhapova, F. A. Yusupov, И. Т. Муркамилов, К. А. Айтбаев, В. В. Фомин, Ж. А. Муркамилова, И. С. Сабиров, З. Р. Райимжанов, Н. А. Реджапова, Ф. А. Юсупов

Πηγή: The Russian Archives of Internal Medicine; Том 9, № 6 (2019); 428-433 ; Архивъ внутренней медицины; Том 9, № 6 (2019); 428-433 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2019-9-6

Θεματικοί όροι: кардиоваскулярные осложнения, glomerular filtration rate, interleukin-6, inflammation, progression, cardiovascular complications Conflict of interests, скорость клубочковой фильтрации, интерлейкин-6, воспаление

Περιγραφή αρχείου: application/pdf

Relation: https://www.medarhive.ru/jour/article/view/981/851; https://www.medarhive.ru/jour/article/view/981/861; Мухин Н.А. Нефрология. Национальное руководство. Краткое издание. Москва. 2018; 608 с.; Моисеев В.С., Мухин Н.А., Смирнов А.В. и др. Сердечнососудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Российский кардиологический журнал. 2014; 8: 7-37. DOI:10.15829/1560-4071-2014-8-7-37; Levey A.S., Stevens L.A. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2010; 55:4:622-27. DOI:10.1053/j.ajkd.2010.02.337; Муркамилов И.Т., Фомин В.В., Айтбаев К.А. и др. Цитокиновая модель развития сердечно-сосудистых осложнений при хронической болезни почек.Клиническая нефрология. 2017; 2:71-5.; Durlacher-Betzer K., Hassan A., Levi R. et al. Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney international. 2018; 94:2:315-25. DOI:https://doi.org/10.1016/j.kint.2018.02.026; Rops A.L., Jansen E., van der Schaaf A. et al. Interleukin-6 is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice. Kidney international. 2018;93:6:1356-66. DO I :https://doi.org/10.1016/j.kint.2018.01.005; Ракитянская И.А., Рябов С.И. Роль мононуклеаров в поражении нефрона у больных с хроническим гломерулонефритом. сообщение II. Роль интерлейкинов (ИЛ-6 и ИЛ-10) и пролиферации гломерулярных и интерстициальных клеток нефрона в прогрессировании мезангиально-пролиферативного гломерулонефрита. Нефрология. 1998; 2(1): 30-6. DOI:https://doi.org/10.24884/1561-6274-1998-2-1-30-36; Boswell R.N., Yard B.A., Schrama E. et al. Interleukin 6 production by human proximal tubular epithelial cells in vitro: analysis of the effects of interleukin-1a (IL-1a) and other cytokines. Nephrology Dialysis Transplantation. 1994; 9:6: 599-606. DOI:https://doi.org/10.1093/ndt/9.6.599; Naka T., Nishimoto N., Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002;4(Suppl 3): S233-42. DOI:https://doi.org/10.1186/ar565; Akira S., Taga T., Kishimoto T. Interleukin-6 in biologie and medicine. Adv. Immmunol. 1993; 54:1-78. DOI:https://doi.org/10.1016/S0065-2776(08)60532-5; Akchurin O., Akchurin O., Patino E. et al. Interleukin-6 Contributes to the Development of Anemia in Juvenile CKD. Kidney International Reports. 2019; 4(3):470-83. DO I :https://doi.org/10.1016/j.ekir.2018.12.006; Henaut L., Massy Z.A. New insights into the key role of interleukin 6 in vascular calcification of chronic kidney disease. Nephrology Dialysis Transplantation. 2018; 33:4:543-48. DOI:https://doi.org/10.1093/ndt/gfx379; Scarpioni R., Obici L. Renal involvement in autoinflammatory diseases and inflammasome-mediated chronic kidney damage. Clin. Exp. Rheumatol. 2018; 36:54-60.; Levey A.S., Coresh J., Bolton K. et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases. 2002; 39(2 Suppl 1): S1-266.; Hoek F.J., Kemperman F.A., Krediet R.T. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular fi ltration rate. Nephrol Dial Transplant. 2003;18(10): 2024-31. DOI:10.1093/ndt/gfg349; Shalhoub R.J. Pathogenesis of lipoid nephrosis: a disorder of T-cell function.The Lancet. 1974; 304: 7880:556-60. DOI: https://doi.org/10.1016/S0140-6736(74)91880-7; Lutticken C., Wegenka U.M., Yuan J. et al. Association of transcription factor APRF and protein kinase Jak 1 with the interleukin-6 signal transducer gp130.Science. 1994; 263: 5143:89-92.; Band L., Fougueray В., Philippe C. Involvement of tumor necrosis factor L in glomerulas injury.Springer Seminars in Immunopathology.1994;16:53-61.; Муркамилов И.Т., Айтбаев К.А., Фомин В.В. и др. Цитокины и артериальная жесткость на ранней стадии хронической болезни почек: взаимосвязь и прогностическая роль. Клиническая нефрология. 2018; 4: 25-32.; Rose-John S., Heinrich P.C. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 1994;300(Pt2):281-90. DOI:10.1042/bj3000281; Su H., Lei C.T., Zhang C. Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Front. Immunol. 2017; 8:405. DOI:10.3389/fimmu.2017,00405; Muller-Newen G., Kuster A., Hemmann U. et al. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol. 1998; 161:11:6347-6355.; Abbasi F., Chu J.W., Lamendola C. et al. Discrimination between obesita and insulin resistance in the relationship with adiponectin.Diabetes. 2004;53:3:585-90. DOI: https://doi.org/10.2337/diabetes.53.3.585; Abdelnabi A.M., Sadek A.M. Role of interleukin 6 and highly sensitive C-reactive protein in diabetic nephropathy. Egypt J Intern Med. 2018;30(3): 103-9. DOI:10.4103/ejim.ejim_27_18; Klein B., Zhang X.G., Lu Z.Y. et al. Interleukin-6 in human multiple myeloma. Blood. 1995;85(4):863-872.; Айтбаев К.А., Муркамилов И.Т., Фомин В.В. и др. Воспаление при хронической болезни почек: источники, последствия и противовоспалительная терапия. Клиническая медицина. 2018;4(96):314-320. DOI:10.18821/0023-2149-2018-96-4-314-320; https://www.medarhive.ru/jour/article/view/981

Διαθεσιμότητα: https://www.medarhive.ru/jour/article/view/981
https://doi.org/10.20514/2226-6704-2019-9-6-428-433

A new approach in prevention and correction of intradialysis hypotension in patients on maintenance hemodialysis ; Новый подход в профилактике и коррекции интрадиализной гипотензии у больных на программном гемодиализе

Συγγραφείς: I. Yu. Drachev, V. Yu. Shilo, G. S. Dzhulay, И. Ю. Драчев, В. Ю. Шило, Г. С. Джулай

Πηγή: Transplantologiya. The Russian Journal of Transplantation; Том 10, № 4 (2018); 298-307 ; Трансплантология; Том 10, № 4 (2018); 298-307 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2018-10-4

Θεματικοί όροι: кардиоваскулярные осложнения, complications of hemodialysis, intradialysis, hemodialysis, clinical outcomes, blood pressure monitoring, arterial pressure, ultrafiltration rates, dialysis adequacy, cardiovascular complications, осложнения гемодиализа, интрадиализная гипотензия, гемодиализ, клинические исходы, мониторирование артериального давления, артериальное давление, темпы ультрафильтрации, адекватность диализа

Περιγραφή αρχείου: application/pdf

Relation: https://www.jtransplantologiya.ru/jour/article/view/405/469; https://www.jtransplantologiya.ru/jour/article/view/405/478; Джон Т. Даугирдас (ред.). Пер. с англ. А.Ю. Денисов, В.Ю. Шило. Руководство по диализу. М.; 2003. 172 с.; Chang T.I., Friedman G.D., Cheung A.K., et al. Systolic blood pressure and mortality in prevalent hemodialysis patients in the HEMO study. J. Hum. Hypertens. 2011;25(2):98–105. PMID:20410919 DOI:10.1038/jhh.2010.42; Flythe J.E., Xue H., Lynch K.E., et al. Association of mortality risk with various definitions of intradialytic hypotension. J. Am. Soc. Nephrol. 2015;26(3):724–34. DOI:10.1681/ASN.2014020222.; McIntyre C.W., Odudu A. Hemodialysis-associated cardiomyopathy: a newly defined disease entity. Semin. Dial. 2014;27(2):87–97. PMID:24738144; Burton J.O., Jefferies H.J., Selby N.M., McIntyre C.W. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin. J. Am. Soc. Nephrol. 2009;4(5):914–920. PMID:19357245 DOI:10.2215/CJN.03900808; Chang T.I., Paik J., Greene T., Desai M., et al. Intradialytic hypotension and vascular access thrombosis. J. Am. Soc. Nephrol. 2011;22(8):1526– 1533. PMID:21803971 DOI:10.1681/ASN.2010101119; Драчев И.Ю., Джулай Г.С., Шило В.Ю. Выживаемость пациентов в зависимости от значений преддиализного пульсового давления и его вариаций в ходе процедуры гемодиализа в 5-летнем когортном исследовании. Врач-аспирант. 2018;86(1):26–36.; Machek P., Jirka T., Moissl U., et al. Guided optimization of fluid status in haemodialysis patients. Nephrol. Dial. Transplant. 2010;25(2):538–544. PMID:19793930DOI:10.1093/ndt/gfp487; Yu A.W., Nawab Z.M., Barnes W.E., et al. Splanchnic erythrocyte content decreases during hemodialysis: a new compensatory mechanism for hypovolemia. Kidney Int. 1997;51(6):1986–1990. PMID:9186892; Movilli E., Gaggia P., Zubani R., et al. Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicenter study. Nephrol. Dial. Transplant. 2007;22(2):3547–3552. PMID:17890254 DOI:10.1093/ndt/gfm466; Тронина О.А., Эттингер О.А., Гендлин Г.Е. и др. Сравнение показателей гемодинамики и эластических свойств сосудов у пациентов на программном гемодиализе (ПГД) и после аллотрансплантации почки (АТП). Нефрология и диализ. 2005;7(3):343– 344.; Assimon M.M., Wenger J.B., Wang L., Flythe J.E. Ultrafiltration Rate and Mortality in Maintenance Hemodialysis Patients. Am. J. Kidney Dis. 2016;68(6):911–922.PMID:27575009 DOI:10.1053/j.ajkd.2016.06.020; Шило В.Ю., Драчев И.Ю. Влияние показателей пред и постдиализного артериального давления и его вариаций в ходе процедуры гемодиализа на выживаемость пациентов в 5-летнем когортном исследовании в условиях реальной клинической практики. Клиническая нефрология. 2017;(3):14–22.; Burton J.O., Jefferies H.J., Selby N.M., McIntyre C.W. Hemodialysisinduced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin. J. Am. Soc. Nephrol. 2009;4(12):1925– 1931. PMID:19808220 DOI:10.2215/CJN.04470709; Flythe J.E., Inrig J.K., Shafi T., et al. Association of intradialytic blood pressure variability with increased all-cause and cardiovascular mortality in patients treated with long-term hemodialysis. Am. J. Kidney Dis. 2013;61(6):966– 974. PMID:23474007 DOI:10.1053/j.ajkd.2012.12.023; Chazot C., Jean G. The advantages and challenges of increasing the duration and frequency of maintenance dialysis sessions. Nat. Clin. Prac. Nephrol. 2009;5(1):34 44. PMID:19030001 DOI:10.1038/ncpneph0979; A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N. Engl. J. Med. 2017;377(25):2506 PMID:29262284 DOI:10.1056/NEJMx170008; Mancini E., Mambelli E., Irpinia M., et al. Prevention of dialysis hypotension episodes using fuzzy logic control system. Nephrol. Dial. Transplant. 2007;22(5):1420–1427. PMID:17299006 DOI:10.1093/ndt/gfl799; https://www.jtransplantologiya.ru/jour/article/view/405

Διαθεσιμότητα: https://www.jtransplantologiya.ru/jour/article/view/405
https://doi.org/10.23873/2074-0506-2018-10-4-298-307

RATIONAL USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS. CLINICAL GUIDELINES ; РАЦИОНАЛЬНОЕ ИСПОЛЬЗОВАНИЕ НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ. КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

Συγγραφείς: A. E. Karateev, E. L. Nasonov, V. T. Ivashkin, A. I. Martynov, N. N. Yakhno, G. P. Arutyunov, L. I. Alekseeva, G. R. Abuzarova, M. A. Evseev, M. L. Kukushkin, S. S. Kopenkin, A. M. Lila, T. L. Lapina, D. S. Novikova, T. V. Popkova, A. P. Rebrov, K. V. Skorobogatykh, N. V. Chichasova, А. Е. Каратеев, Е. Л. Насонов, В. Т. Ивашкин, А. И. Мартынов, Н. Н. Яхно, Г. П. Арутюнов, Л. И. Алексеева, Г. Р. Абузарова, М. А. Евсеев, М. Л. Кукушкин, С. С. Копенкин, А. М. Лила, Т. Л. Лапина, Д. С. Новикова, Т. В. Попкова, А. П. Ребров, К. В. Скоробогатых, Н. В. Чичасова

Πηγή: Rheumatology Science and Practice; Vol 56 (2018): приложение 1; 1-29 ; Научно-практическая ревматология; Vol 56 (2018): приложение 1; 1-29 ; 1995-4492 ; 1995-4484 ; 10.14412/rjtao20180

Θεματικοί όροι: гепатотоксические реакции, nonsteroidal anti-inflammatory drugs, efficacy, safety, NSAID gastropathy, NSAID enteropathy, cardiovascular events, nephrotoxicity, hepatotoxic reactions, нестероидные противовоспалительные препараты, эффективность, безопасность, НПВП-гастропатия, НПВП-энтеропатия, кардиоваскулярные осложнения, нефротоксичность

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2536/1691; Насонов ЕЛ, Яхно НН, Каратеев АЕ и др. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016;54(3):247-65 [Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of treatment for musculoskeletal pain: Interdisciplinary consensus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):247-65 (In Russ.)]. doi:10.14412/1995-4484-2016-247-265; Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 Nov 28;386(10009):2145-91. doi:10.1016/S0140-6736(15)61340-X. Epub 2015 Aug 28.; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)]. ISBN 978-5-9704-4261-6.; Здравоохранение в России. 2017: Статистический сборник. Москва: Росстат; 2017. 170 с. [Zdravookhranenie v Rossii. 2017: Statisticheskii sbornik [Public health in Russia. 2017: Statistical Digest]. Moscow: Rosstat; 2017. 170 p. (In Russ.)]. ISBN 978-5-89476-448-1. http://www.gks.ru; Доступно по ссылке: https://www.iqvia.com/our-customers/pharmaceutical-manufacturers [Available from: https://www.iqvia.com/ our-customers/pharmaceutical-manufacturers].; Шостак НА, Рябкова АА, Савельев ВС, Малярова ЛН. Желудочно-кишечное кровотечение как осложнение гастропатий, связанных с приемом нестероидных противовоспалительных препаратов. Терапевтический архив. 2003;(5):70-4 [Shostak NA, Ryabkova AA, Savel'ev VS, Malyarova LN. Gastrointestinal bleeding as a complication of gastropathy associated with use of nonsteroidal antiinflammatory drugs. Terapevticheskii Arkhiv. 2003;(5):70-4 (In Russ.)].; Евсеев МА. НПВП-индуцированные гастродуоденальные язвы, осложненные кровотечением. Русский медицинский журнал. 2006;(15):1099-107 [Evseev MA. NSAID-induced gastroduodenal ulcer complicated by bleeding. Russkii Meditsinskii Zhurnal. 2006;(15):1099-107 (In Russ.)].; Гельфанд БР, Проценко ДН, Бабаянц АВ, Каратеев АЕ. Острые кровотечения из верхних отделов желудочно-кишечного тракта: от эпидемиологии до формирования концепции консервативной терапии. Инфекции в хирургии. 2013;(4):11-7 [Gel'fand BR, Protsenko DN, Babayants AV, Karateev AE. Severe bleeding from the upper parts of the gastrointestinal tract: from epidemiology to the formation of the concept of conservative therapy. Infektsii v Khirurgii. 2013;(4):11-7 (In Russ.)].; Jafar W, Jafar AJN, Sharma A. Upper gastrointestinal haemorrhage: an update. Frontline Gastroenterol. 2016 Jan;7(1):32-40. doi:10.1136/flgastro-2014-100492. Epub 2014 Oct 10.; Del Piano M, Bianco MA, Cipolletta L, et al. The «Prometeo» study: online collection of clinical data and outcome of Italian patients with acute nonvariceal upper gastrointestinal bleeding. J Clin Gastroenterol. 2013 Apr;47(4):e33-7. doi:10.1097/MCG. 0b013e3182617dcc; Nagasue T, Nakamura S, Kochi S, et al. Time trends of the impact of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs on peptic ulcer bleeding in Japanese patients. Digestion. 2015;91(1):37-41. doi:10.1159/000368810. Epub 2015 Jan 20.; Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013;16(5):821-47. doi:10.18433/J3VW2F; Каратеев АЕ, Насонов ЕЛ, Яхно НН. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-23 [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(1):4-23 (In Russ.)]. doi:10.14412/1996-7012-2015-1-4-23; Насонов ЕЛ, Ивашкин ВТ, Яхно НН и др. Проект Национальных клинических рекомендаций (основные положения) Ассоциации ревматологов России, Российской гастроэнтерологической ассоциации, Российского общества по изучению боли «Рациональное использование нестероидных противовоспалительных препаратов» (По результатам совещания группы экспертов, г. Москва, 01.04.2017). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):69-75 [Nasonov EL, Ivashkin VT, Yakhno NN, et al. Draft National Clinical Recommendations (main provisions) of the Association of Rheumatologists of Russia, the Russian Gastroenterological Association, the Russian Society for the Study of Pain «Rational Use of Non-steroidal Anti-Inflammatory Drugs» (Based on the results of a meeting of the expert group, Moscow, April 1, 2017). Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2017;27(5):69-75 (In Russ.)]. doi:10.22416/1382-4376-2017-27-5-69-75; Доступно по ссылке: http://www.grls.rosminzdrav.ru/ [Available from: http://www.grls.rosminzdrav.ru/].; Lee C, Straus WL, Balshaw R, et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004 Oct 15;51(5):746-54. doi:10.1002/art.20698; Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008 Apr;12(11): 1-278, iii. doi:10.3310/hta12110; Stam W, Jansen J, Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. Open Rheumatol J. 2012;6:6-20. doi:10.2174/1874312901206010006. Epub 2012 Apr 3.; Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, doubleblind, controlled study. Ann Rheum Dis. 2008 Mar;67(3):323-9. Epub 2007 Jul 6.; Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000396. doi:10.1002/14651858.CD000396.pub3; Puljak L, Marin A, Vrdoljak D, et al. Celecoxib for osteoarthritis. Cochrane Database Syst Rev. 2017 May 22;5:CD009865. doi:10.1002/14651858.CD009865.pub2; Fidahic M, Jelicic Kadic A, Radic M, Puljak L. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2017 Jun 9;6:CD012095. doi:10.1002/14651858.CD012095.pub2; Derry S, Moore RA. Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2013 Oct 22;10:CD004233. doi:10.1002/14651858. CD004233.pub4; Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017 Jul 8;390(10090):e21-e33. doi:10.1016/S0140-6736(17)31744-0; Combe B, Velicitat P, Garzon N, Bluhmki E. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res. 2001 Mar;50 Suppl 1:S10-6.; Neighbor ML, Puntillo KA. Intramuscular ketorolac vs oral ibuprofen in emergency department patients with acute pain. Acad Emerg Med. 1998 Feb;5(2):118-22. doi:10.1111/j.1553-2712.1998.tb02595.x; Shrestha M, Morgan DL, Moreden JM, et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med. 1995 Dec;26(6):682-6. doi:10.1016/S0196-0644(95)70037-4; Wright JM, Price SD, Watson WA. NSAID use and efficacy in the emergency department: single doses of oral ibuprofen versus intramuscular ketorolac. Ann Pharmacother. 1994 Mar;28(3):309-12. doi:10.1177/106002809402800301; Dougados M, Listrat V, Duchesne L, Amor B. Comparative efficacy of ketoprofen related to the route of administration (intramuscular or per os). A double-blind study versus placebo in rheumatoid arthritis. Rev Rhum Mal Osteoartic. 1992 Nov 30;59(11):769-73.; Tramer MR, Williams JE, Carroll D, et al. Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand. 1998;42(1):71-9. doi:10.1111/j.1399-6576.1998.tb05083.x; Motov S, Yasavolian M, Likourezos A, et al. Comparison of Intravenous Ketorolac at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2017 Aug;70(2):177-84. doi:10.1016/j.annemergmed.2016.10.014. Epub 2016 Dec 16.; Fraquelli M, Casazza G, Conte D, Colli A. Non-steroid antiinflammatory drugs for biliary colic. Cochrane Database Syst Rev. 2016 Sep 9;9:CD006390. doi:10.1002/14651858.CD006390.pub2 [Epub ahead of print].; Pathan SA, Mitra B, Cameron PA. A Systematic Review and Meta-analysis Comparing the Efficacy of Nonsteroidal Antiinflammatory Drugs, Opioids, and Paracetamol in the Treatment of Acute Renal Colic. Eur Urol. 2018 Apr;73(4):583-95. doi:10.1016/j.eururo.2017.11.001. Epub 2017 Nov 22.; Machado GC, Maher CG, Ferreira PH, et al. Non-steroidal antiinflammatory drugs for spinal pain: a systematic review and metaanalysis. Ann Rheum Dis. 2017 Jul;76(7):1269-78. doi:10.1136/annrheumdis-2016-210597. Epub 2017 Feb 2.; Rossi L, Conen D. Intramuscular injections – an outdated form of administration? 6 cases of Staphylococcus aureus sepsis following intramuscular injections. Schweiz Med Wochenschr. 1995 Aug 8;125(31-32):1477-82 (In Germ.).; Rotman-Pikielny P, Levy Y, Eyal A, Shoenfeld Y. Pyomyositis or «injectiositis» – Staphylococcus aureus multiple abscesses following intramuscular injections. Isr Med Assoc J. 2003 Apr;5(4):295-6.; Frick S, Cerny A. Necrotizing fasciitis due to Streptococcus pneumoniae after intramuscular injection of nonsteroidal anti-inflammatory drugs: report of 2 cases and review. Clin Infect Dis. 2001 Sep 1;33(5):740-4. doi:10.1086/322592 Epub 2001 Aug 6.; Adil M, Amin SS, Arif T. Nicolau's syndrome: A rare but preventable iatrogenic disease. Acta Dermatovenerol Croat. 2017 Oct;25(3):251-3.; Kim SK, Kim TH, Lee KC. Nicolau syndrome after intramuscular injection: 3 cases. Arch Plast Surg. 2012 May;39(3):249-52. doi:10.5999/aps.2012.39.3.249. Epub 2012 May 10.; Luton K, Garcia C, Poletti E, Koester G. Nicolau Syndrome: three cases and review. Int J Dermatol. 2006 Nov;45(11):1326-8. doi:10.1111/j.1365-4632.2006.02674.x; Bjordal J, Klovning A, Ljunggren A, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain. 2007 Feb;11(2):125-38. doi:10.1016/j.ejpain.2006.02.013. Epub 2006 May 8.; Pincus T, Koch G, Lei H, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004 Aug;63(8):931-9. doi:10.1136/ard.2003. 020313. Epub 2004 Apr 13.; Daniels SE, Bandy DP, Christensen SE, et al. Evaluation of the dose range of etoricoxib in an acute pain setting using the postoperative dental pain model. Clin J Pain. 2011 Jan;27(1):1-8. doi:10.1097/AJP.0b013e3181ed0639; DeLemos B, Xiang J, Benson C, et al. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. Am J Ther. 2011 May;18(3):216-26. doi:10.1097/MJT. 0b013e3181cec307; Innes G, Croskerry P, Worthington J, et al. Ketorolac versus acetaminophen-codeine in the emergency department treatment of acute low back pain. J Emerg Med. 1998 Jul-Aug;16(4):549-56. doi:10.1016/S0736-4679(98)00044-4; O'Donnell JB, Ekman EF, Spalding WM, et al. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, doubleblind, 6-week studies. J Int Med Res. 2009 Nov-Dec;37(6):1789-802. doi:10.1177/147323000903700615; Smith SR, Deshpande BR, Collins JE, et al. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. 2016 Jun;24(6):962-72. doi:10.1016/j.joca. 2016.01.135. Epub 2016 Feb 1.; Кукушкин МЛ. Алгоритмы диагностики и лечения боли в спине. Русский медицинский журнал. 2014;(11):844-8. [Kukushkin ML. Algorithms for diagnosis and treatment of back pain. Russkii Meditsinskii Zhurnal. 2014;(11):844-8 (In Russ.)].; Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet. 2016 Oct 10. pii: S0140-6736(16)30970-9. doi:10.1016/S0140-6736(16)30970-9; Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Feb 14. doi:10.7326/M16-2367; Enthoven WT, Roelofs PD, Deyo RA, et al. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016 Feb 10;2:CD012087. doi:10.1002/14651858. CD012087; Malanga G, Wolff E. Evidence-informed management of chronic low back pain with nonsteroidal anti-inflammatory drugs, muscle relaxants, and simple analgesics. Spine J. 2008 Jan-Feb;8(1): 173-84. doi:10.1016/j.spinee.2007.10.013; Kuritzky L, Samraj GP. Nonsteroidal anti-inflammatory drugs in the treatment of low back pain. J Pain Res. 2012;5:579-90. doi:10.2147/JPR.S6775. Epub 2012 Nov 28.; White AP, Arnold PM, Norvell DC, et al. Pharmacologic management of chronic low back pain: synthesis of the evidence. Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S131-43. doi:10.1097/ BRS.0b013e31822f178f; Barrington JW, Halaszynski TM, Sinatra RS, et al. Perioperative pain management in hip and knee replacement surgery. Am J Orthop (Belle Mead NJ). 2014 Apr;43(4 Suppl):S1-S16.; Elmallah RK, Cherian JJ, Pierce TP, et al. New and Common Perioperative Pain Management Techniques in Total Knee Arthroplasty. J Knee Surg. 2016 Feb;29(2):169-78. doi:10.1055/s0035-1549027. Epub 2015 Apr 18.; Regan DW, Kashiwagi D, Dougan B, et al. Update in perioperative medicine: practice changing evidence published in 2016. Hosp Pract (1995). 2017 Oct;45(4):158-64. doi:10.1080/21548331.2017. 1359060. Epub 2017 Jul 28.; De Oliveira GS Jr, Agarwal D, Benzon HT. Perioperative single dose ketorolac to prevent postoperative pain: a meta-analysis of randomized trials. Anesth Analg. 2012 Feb;114(2):424-33. doi:10.1213/ANE.0b013e3182334d68. Epub 2011 Sep 29.; Cepeda MS, Carr DB, Miranda N, et al. Comparison of morphine, ketorolac, and their combination for postoperative pain: results from a large, randomized, double-blind trial. Anesthesiology. 2005 Dec;103(6):1225-32. doi:10.1097/00000542-200512000-00018; McDaid C, Maund E, Rice S, et al. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side effects after major surgery: a systematic review. Health Technol Assess. 2010 Mar;14(17):1-153, iii-iv. doi:10.3310/hta14170; Vardy J, Agar M. Nonopioid drugs in the treatment of cancer pain. J Clin Oncol. 2014 Jun 1;32(16):1677-90. doi:10.1200/JCO.2013. 52.8356. Epub 2014 May 5.; Rodriguez MJ, Contreras D, Galvez R, et al. Double-blind evaluation of short-term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain. 2003 Jul;104(1-2):103-10. doi:10.1016/S0304-3959(02)00470-0; Mercadante S, Fulfaro F, Casuccio A. A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer. 2002 Jul;38(10):1358-63. doi:10.1016/S0959-8049(02)00102-8; Pannuti F, Robustelli della Cuna G, Ventaffrida V, et al. A doubleblind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group. Tumori. 1999 Mar-Apr;85(2):96-100.; Liu Z, Xu Y, Liu ZL, et al. Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial. Int J Clin Oncol. 2017 Oct;22(5):980-5. doi:10.1007/s10147-017-1133-y. Epub 2017 May 8.; Gaertner J, Stamer UM, Remi C, et al. Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice. Palliat Med. 2017 Jan;31(1):26-34. doi:10.1177/0269216316655746. Epub 2016 Jul 20.; McNicol E, Strassels SA, Goudas L, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD005180. doi:10.1002/14651858. CD005180; Derry S, Wiffen PJ, Moore RA, et al. Oral nonsteroidal antiinflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database Syst Rev. 2017 Jul 12;7:CD012638. doi:10.1002/14651858.CD012638.pub2; Reid J, Hughes CM, Murray LJ, et al. Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review. Palliat Med. 2013 Apr;27(4): 295-303. doi:10.1177/ 0269216312441382. Epub 2012 Mar 26.; Luyten FP, Geusens P, Malaise M, et al. A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. Ann Rheum Dis. 2007 Jan;66(1):99-106. doi:10.1136/ard. 2006.052308. Epub 2006 Jun 30.; Strand V, Simon LS, Dougados M, et al. Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol. 2011 Dec;38(12):2625-34. doi:10.3899/jrheum.110636. Epub 2011 Nov 1.; Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl): S3-11. doi:10.1016/j.semarthrit.2015.11.010. Epub 2015 Dec 2.; Qaseem A, Harris RP, Forciea MA, et al. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Jan 3;166(1):58-68. doi:10.7326/M16-0570. Epub 2016 Nov 1.; Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42. doi:10.1136/annrheumdis2016-209707. Epub 2016 Jul 25.; Van Durme CM, Wechalekar MD, Buchbinder R, et al. Nonsteroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014 Sep 16;(9):CD010120. doi:10.1002/ 14651858.CD010120.pub2; Schumacher H, Boice J, Dahikh D, et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ. 2002;324:1488-92. doi:10.1136/bmj.324.7352. 1488; Zhang S, Zhang Y, Liu P, et al. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol. 2016 Jan;35(1):151-8. doi:10.1007/s10067-015-2991-1. Epub 2015 Jun 24.; Becker MA, Fitz-Patrick D, Choi HK, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct;45(2):174-83. doi:10.1016/j.semarthrit.2015.05.005. Epub 2015 May 21.; Blachier M, Canoui-Poitrine F, Dougados M, et al. Factors associated with radiographic lesions in early axial spondyloarthritis. Results from the DESIR cohort. Rheumatology (Oxford). 2013 Sep; 52(9):1686-93. doi:10.1093/rheumatology/ket207. Epub 2013 Jun 13.; Poddubnyy D, van der Heijde D. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Rheum Dis Clin North Am. 2012 Aug;38(3):601-11. doi:10.1016/j.rdc. 2012.08.005. Epub 2012 Sep 15.; Kroon FP, van der Burg LR, Ramiro S, et al. Non-steroidal antiinflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015 Jul 17;(7):CD010952. doi:10.1002/14651858.CD010952.pub2; Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun;76(6):978-91. doi:10.1136/ annrheumdis-2016-210770. Epub 2017 Jan 13.; Wanders A, van der Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756-65. doi:10.1002/art.21054; Rannou F, Pelletier JP, Martel-Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S18-21. doi:10.1016/j.semarthrit.2015.11.007. Epub 2015 Dec 2.; Altman R, Barthel H. Topical therapies for osteoarthritis. Drugs. 2011 Jul 9;71(10):1259-79. doi:10.2165/11592550-000000000-00000; Kneer W, Rother I, Rother M, et al. A multiple-dose, open-label, safety, compliance, and usage evaluation study of epicutaneously applied Diractin (ketoprofen in Transfersome) in joint/musculoskeletal pain or soft tissue inflammation. Curr Drug Saf. 2009 Jan;4(1):5-10. doi:10.2174/157488609787354468; Mazieres B, Rouanet S, Velicy J, et al. Topical ketoprofen patch (100 mg) for the treatment of ankle sprain: a randomized, doubleblind, placebo-controlled study. Am J Sports Med. 2005 Apr; 33(4):515-23. doi:10.1177/0363546504268135 Epub 2005 Feb 8.; Baraf HS, Gloth FM, Barthel HR, et al. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, doubleblind, parallel-group, placebo-controlled, multicentre trials. Drugs Aging. 2011 Jan 1;28(1):27-40. doi:10.2165/11584880-000000000-00000; Derry S, Moore RA, Gaskell H, et al. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015 Jun 11;(6):CD007402. doi:10.1002/14651858.CD007402.pub3; Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015 Feb 20;8:105-18. doi:10.2147/JPR.S75160. eCollection 2015.; Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal AntiInflammatory Drugs. Gastroenterology. 2018 Feb;154(3):500-14. doi:10.1053/j.gastro.2017.10.049. Epub 2017 Dec 6.; Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S3. doi:10.1186/ar4175. Epub 2013 Jul 24.; Otani K, Tanigawa T, Watanabe T, et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22-8. doi:10.1159/ 000452356. Epub 2017 Jan 5.; Lain L. Proton pump inhibitor co-therapy with nonsteroidal antiinflammatory drugs – nice or necessary? Rev Gastroenterol Disord. 2004;4 Suppl 4:S33-41.; Fries JF, Murtagh KN, Bennett M, et al. The rise and decline of nonsteroidal anti-inflammatory drag-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. 2004 Aug;50(8):2433-40. doi:10.1002/art.20440; Brooks J, Warburton R, Beales IL. Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance. Ther Adv Chronic Dis. 2013 Sep;4(5):206-22. doi:10.1177/ 2040622313492188; Scheiman J. NSAID-induced Gastrointestinal Injury: A Focused Update for Clinicians. J Clin Gastroenterol. 2016 Jan;50(1):5-10. doi:10.1097/MCG.0000000000000432; Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol. 2007 Sep;5(9): 1040-5. doi:10.1016/j.cgh.2007.04.031 Epub 2007 Jul 10.; Adebayo D, Bjarnason I. Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J. 2006 Mar;82(965):186-91. doi:10.1136/ pgmj.2005.039586; Taki M, Oshima T, Tozawa K, et al. Analysis of risk factors for colonic diverticular bleeding and recurrence. Medicine (Baltimore). 2017 Sep;96(38):e8090. doi:10.1097/MD.0000000000008090; Nagata N, Niikura R, Yamada A, et al. Acute Middle Gastrointestinal Bleeding Risk Associated with NSAIDs, Antithrombotic Drugs, and PPIs: A Multicenter Case-Control Study. PLoS One. 2016 Mar 15;11(3):e0151332. doi:10.1371/ journal.pone.0151332. eCollection 2016.; Goldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther. 2007 May 15;25(10):1211-22. doi:10.1111/j.1365-2036.2007.03312.x; Hawkey CJ, Ell C, Simon B, et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol. 2008 May;6(5):536-44. doi:10.1016/j.cgh. 2007.12.023. Epub 2008 Jan 31.; Stein J, Connor S, Virgin G, et al. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol. 2016 Sep 21;22(35):7908-25. doi:10.3748/wjg.v22.i35.7908; Sands G, Shell B, Zhang R. Adverse events in patients with blood loss: a pooled analysis of 51 clinical studies from the celecoxib clinical trial database. Open Rheumatol J. 2012;6:44-9. doi:10.2174/1874312901206010044. Epub 2012 May 11.; Mallen SR, Essex MN, Zhang R. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2011 Jul;27(7):1359-66. doi:10.1185/03007995.2011. 581274. Epub 2011 May 12.; Lanas A. A review of the gastrointestinal safety data – a gastroenterologist's perspective. Rheumatology (Oxford). 2010 May;49 Suppl 2:ii3-10. doi:10.1093/rheumatology/keq058; Каратеев АЕ, Насонов ЕЛ. Неязвенная диспепсия, ассоциированная с приемом НПВП: возможность применения антацидных препаратов. Научно-практическая ревматология. 2003;41(2):28-30 [Karateev AE, Nassonov EL. Non-ulcer dyspepsia associated with NSAID intake: possibility of antacid drugs application. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2003;41(2):28-30 (In Russ.)]. doi:10.14412/1995-4484-2003-765; Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006 Feb;4(2):196-202. doi:10.1016/ S1542-3565(05)00980-8; Kefalakes H, Stylianides TJ, Amanakis G, Kolios G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol. 2009 Oct;65(10):963-70. doi:10.1007/s00228-009-0719-3. Epub 2009 Aug 27.; Kvasnovsky CL, Aujla U, Bjarnason I. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand J Gastroenterol. 2015 Mar;50(3):255-63. doi:10.3109/ 00365521.2014.966753. Epub 2014 Oct 14.; Hensley A, Beales IL. Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study. Pharmaceuticals (Basel). 2015 Sep 7;8(3): 512-24. doi:10.3390/ph8030512; Насонов ЕЛ. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой. Клиническая фармакология и терапия. 2003;12(1):64-9 [Nasonov EL. Analgesic therapy in rheumatology: a journey between Scylla and Charybdis. Klinicheskaya Farmakologiya i Terapiya 2003;12(1):64-9 (In Russ.)].; Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol. 2018 Feb 21. doi:10.1111/bph.14167 [Epub ahead of print].; Harris RC, Breyer MD. Update on Cyclooxygenase-2 Inhibitors. Clin J Am Soc Nephrol. 2006 Mar;1(2):236-45. doi:10.2215/CJN. 00890805. Epub 2006 Feb 1.; Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension. 2004 Mar;43(3):525-30. doi:10.1161/01. HYP.0000116221.27079.ea Epub 2004 Jan 19.; Singh G, Miller JD, Lee FH, et al. Pevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination survey. Am J Manag Care. 2002;8(Suppl 15):83-91.; Harley C, Wagner S. The prevalence of cardiovascular risk factors in parients prescribing anti-inflammatory drugs; data from managed care. Clin Ther. 2003;25:139-49. doi:10.1016/S0149-2918(03)90017-8; Curhan G, Willet W, Rosner B, Stampfer M. Frequency оf analgestic use and risk of hypertension in younger woman. Arch Intern Med. 2002;162:2204-8. doi:10.1001/archinte.162.19.2204; Formam J, Stampfer M, Curhan G. Non-narcotic analgetic dose and risk of incident hypertension in US women. Hypertension. 2005 Sep;46(3):500-7. doi:10.1161/01.HYP.0000177437. 07240.70. Epub 2005 Aug 15.; Solomon D, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004;44:140-5. doi:10.1161/01.HYP.0000136134. 31846.83; Silverstein F, Faich G, Goldstein J, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA. 2000;284:1247-55. doi:10.1001/jama.284.10.1247; Singh G, Fort J, Goldstein J, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med. 2006;119:255-66. doi:10.1016/j.amjmed.2005.09.054; Cannon C, Curtis S, FitzGerald G, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771-81. doi:10.1016/S0140-6736(06)69666-9; Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519-29. doi:10.1056/NEJMoa1611593. Epub 2016 Nov 13.; Aw T, Haas S, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165(5):490-6. doi:10.1001/archinte.165.5.ioi50013; Chan C, Reid C, Aw T, et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009;27(12):2332-41. doi:10.1097/HJH.0b013e3283310dc9; Watkins J, Abbott E, Hensby C, et al. Attenuation of hypotensive effect of propranalol and thiaside diuretics by indomethacin. Br Med J. 1980;281:702-5. doi:10.1136/bmj.281.6242.702; Polonia J, Boaventure J, Gama G, et al. Influence of nonsteroidal antiinflammatory drugs on renal function and 24-hour blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens. 1995;13:925-31. doi:10.1097/00004872-199508000-00014; Wong D, Spence J, Lamki L, et al. Effect of nonsteroidal antiinflammatory drugs on control of hypertension of beta-blockers and diuretics. Lancet. 1986;1:997-1001. doi:10.1016/S0140-6736 (86)91271-7; Baez M, Alvarez C, Weilder D. Effects of the non-steroidal antiinflammatory drugs, piroxicam or sulindac, on the antihypertensive action of propranolol and verapamil. J Hypertension. 1987; Suppl. 5:563-6.; Cinquegrani M, Liang C. Antihypertensive effects of pinacidil in patients with and without indomethacin pretreatment. Clin Exp Hypertension. 1988;10:411-31. doi:10.3109/10641968809033901; Hardy B, Bartle W, Myers M, et al. Effects of indomethacin on the pharmakokinetics of felodipine. Br J Clin Pharmacol. 1988;26:557-67. doi:10.1111/j.1365-2125.1988.tb05295.x; Houston M, Weir M, Gray J, et al. The effects of non-steroidal antiinflammatory drugs on blood pressure of patients with hypertension controlled by verapamil. Arch Intern Med. 1995;155: 1049-54. doi:10.1001/archinte.1995.00430100075009; Klassen D, Goadfriend T, Schuma A, et al. Assesment of Blood pressure during treatment with naproxen of ibuprofen in hypertensive patients treated with hydrochlorthiazide. J Clin Pharmacol. 1993;33(10): 971-8. doi:10.1002/j.1552-4604.1993.tb01932.x; Johnson D, Hisel T, Phillips B. Effect of cyclooxygenase-2 inhibitors on blood pressure. Ann Pharmacother. 2003;37:442-6. doi:10.1345/aph.1C277; Whelton A, Fort J, Puma J, et al. SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85-95. doi:10.1097/00045391-200103000-00003; Whelton A, White W, Bello A, et al. SUCCESS VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systolic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-63. doi:10.1016/S0002-9149(02)02661-9; Dilger K, Herrlinger C, Peters J, et al. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol. 2002;42:985-94. doi:10.1177/0091270002042009005; Pavlicevic I, Kuzmanic M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008 Fall;15(3): e372-82. Epub 2008 Oct 24.; Aljadhey H, Tu W, Hansen RA, et al. Comparative effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovasc Disord. 2012 Oct 24;12:93. doi:10.1186/1471-2261-12-93; Villa J, Cano A, Franco D, et al. Clinical relevance of drug interactions between nonsteroidal antiinflammatory drugs (NSAIDs) and antihypertensives. Aten Primaria. 2014 Nov;46(9):464-74 (In Span.). doi:10.1016/j.aprim.2013.11.010. Epub 2014 Mar 22.; Elliott WJ. Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality? Curr Hypertens Rep. 2010 Aug;12(4):258-66. doi:10.1007/ s11906-010-0120-8; White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007 Jan 1;99(1):91-8. doi:10.1016/ j.amjcard.2006.07.069. Epub 2006 Nov 10.; Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002 Apr 19;296(5567):539-41. doi:10.1126/science.1068711; Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenes an opportunities. J Clin Invest. 2006 Jan;116(1):4-15. doi:10.1172/JCI27291; Schaeverbeke T, Heloire F, Deray G. How to watch over a patient treated with a NSAID in relation to the cardiovascular and renal risk? Presse Med. 2006 Sep;35 Suppl 1:41-6. doi:10.1016/S0755-4982(06)74939-9; Laine L, White WB, Rostom A, Hochberg M. COX-2 Selective Inhibitors in the Treatment of Osteoarthritis. Semin Arthritis Rheum. 2008 Dec;38(3):165-87. doi:10.1016/j.semarthrit.2007. 10.004. Epub 2008 Jan 4.; Vonkeman HE, Brouwers JR, van de Laar MA. Understanding the NSAID related risk of vascular events. BMJ. 2006 Apr 15;332(7546):895-8. doi:10.1136/bmj.332.7546.895; Fosbol EL, Kober L, Torp-Pedersen C, Gislason GH. Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. Expert Opin Drug Saf. 2010 Nov;9(6):893-903. doi:10.1517/14740338.2010.501331; Boulakh L, Gislason GH. Treatment with non-steroidal antiinflammatory drugs in patients after myocardial infarction – a systematic review. Expert Opin Pharmacother. 2016 Jul;17(10): 1387-94. doi:10.1080/14656566.2016.1186648. Epub 2016 May 23.; Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006 Jun 27;113(25): 2906-13. doi:10.1161/CIRCULATIONAHA.106.616219. Epub 2006 Jun 19.; Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015 Feb 24;313(8):805-14. doi:10.1001/jama.2015.0809; Richman IB, Owens DK. Aspirin for Primary Prevention. Med Clin North Am. 2017 Jul;101(4):713-24. doi:10.1016/j.mcna.2017. 03.004; Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effect of aspirin. N Engl J Med. 2001 Dec 20;345(25):1809-17. doi:10.1056/NEJMoa003199; Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005 Apr 19;45(8):1295-301. doi:10.1016/j.jacc. 2005.01.045; Van Solingen RM, Rosenstein ED, Mihailescu G, et al. Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin. Am J Med. 2001 Sep;111(4):285-9. doi:10.1016/S0002-9343(01)00838-5; Wilner KD, Rushing M, Walden C, et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthe volunteers. J Clin Pharmacol. 2002 Sep;42(9):1027-30. doi:10.1177/ 0091270002042009010; Van Ryn J, Kink-Eiband M, Kuritsch I, et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol. 2004 Jul;44(7):777-84. doi:10.1177/0091270004266623; MacDonald T, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573-4. doi:10.1016/S0140-6736(03)12509-3; Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, GonzalezPerez A. Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation. 2004 Jun 22;109(24):3000-6. doi:10.1161/01.CIR.0000132491.96623. 04. Epub 2004 Jun 14.; Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefit of aspirin on first myocardial infarction by non-steroidal antiinflammatory drugs. Circulation. 2003 Sep 9;108(10):1191-5. doi:10.1161/01.CIR.0000087593.07533.9B Epub 2003 Aug 25.; Hudson M, Baron M, Rahme E, Pilote L. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol. 2005 Aug;32(8):1589-93.; Curtis JP, Wang Y, Portnay EL, et al. Aspirin, ibuprofen, and mortality after myocardial infarction. BMJ. 2003 Dec 6;327(7427): 1322-3. doi:10.1136/bmj.327.7427.1322; Patel TN, Goldberg KC. Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med. 2004 Apr 26;164(8):852-6. doi:10.1001/archinte.164.8.852; Singh G, Graham D, Wang H, et al. Concominant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some non-selective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis. 2006;65 Suppl. II:61 (OP0024 abst).; Ungprasert P, Srivali N, Thongprayoon C. Nonsteroidal Antiinflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational Studies. Clin Cardiol. 2016 Feb;39(2):111-8. doi:10.1002/clc.22502. Epub 2015 Dec 31.; Scott PA, Kingsley GH, Scott DL. Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail. 2008 Nov; 10(11):1102-7. doi:10.1016/j.ejheart.2008.07.013. Epub 2008 Aug 29.; Girouard C, Gregoire JP, Poirier P, Moisan J. Effect of contraindicated drugs for heart failure on hospitalization among seniors with heart failure: A nested case-control study. Medicine (Baltimore). 2017 Mar;96(9):e6239. doi:10.1097/MD. 0000000000006239; Hudson M, Richard H, Pilote L. Different in outcome of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ. 2005 Jun 11;330(7504):1370. doi:10.1136/bmj.330.7504.1370; Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalisation for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford). 2005 May;44(5):677-80. doi:10.1093/rheumatology/keh610. Epub 2005 Mar 22.; Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in eldery patients: a population-based cohort study. Lancet. 2004 May 29;363(9423):1751-6. doi:10.1016/S0140-6736(04)16299-5; Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal antiinflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi:10.1136/bmj.i4857; Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003 Mar;14(2):240-6. doi:10.1097/01.EDE. 0000034633.74133.C3; Bä ck M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J. 2012 Aug;33(15):1928-33. doi:10.1093/eurheartj/ehr421. Epub 2011 Nov 21.; Liu G, Yan YP, Zheng X, et al. Meta-analysis of nonsteroidal anti-inflammatory drug use and risk of atrial fibrillation. Am J Cardiol. 2014 Nov 15;114(10):1523-9. doi:10.1016/j.amjcard.2014.08.015. Epub 2014 Aug 27.; Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ. 2011 Jul 4;343:d3450. doi:10.1136/bmj.d3450; Chuang SY, Hsu PF, Lin F, et al. Association between Nonsteroidal Anti-inflammatory Drugs and Atrial Fibrillation among a Middle-aged Population: A Nationwide Populationbased Cohort. Br J Clin Pharmacol. 2018 Mar 20. doi:10.1111/ bcp.13558 [Epub ahead of print].; Harirforoosh S, Jamali F. Renal adverse effects of non-steroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009 Nov;8(6):669-81. doi:10.1517/14740330903311023; Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal antiinflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017 Aug 1;18(1):256. doi:10.1186/s12882-017-0673-8; Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005 Mar;45(3):531-9. doi:10.1053/j.ajkd.2004.12.005; Nawaz FA, Larsen CP, Troxell ML. Membranous nephropathy and nonsteroidal anti-inflammatory agents. Am J Kidney Dis. 2013 Nov;62(5):1012-7. doi:10.1053/j.ajkd.2013.03.045. Epub 2013 Jun 14.; Lipworth L, Abdel-Kader K, Morse J, et al. High prevalence of non-steroidal anti-inflammatory drug use among acute kidney injury survivors in the southern community cohort study. BMC Nephrol. 2016 Nov 24;17(1):189. doi:10.1186/s12882-016-0411-7; Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal AntiInflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. 2015 Sep;66(3):524-33. doi:10.1161/ HYPERTENSIONAHA.114.05105. Epub 2015 Jul 13.; Mö ller B, Pruijm M, Adler S, et al. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis. 2013 Dec 19. doi:10.1136/ annrheumdis-2013-204078 [Epub ahead of print].; Nderitu P, Doos L, Jones PW, et al. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013 Jun;30(3):247-55. doi:10.1093/fampra/ cms086. Epub 2013 Jan 8.; Souter A. Controversies in the perioperative use of nonsteroidal anti-inflammatory drugs. Anesth Analg. 1994 Dec;79(6):1178-90. doi:10.1213/00000539-199412000-00025; Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and the risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA. 1996 Feb 7;275(5):376-82. doi:10.1001/jama.1996.03530290046036; Weber EW, Slappendel R, Durieux ME, et al. COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. Eur J Anaesthesiol. 2003 Dec;20(12):963-6. doi:10.1097/00003643-200312000-00005; Bricker SR, Savage ME, Hanning CD. Perioperative blood loss and non-steroidal anti-inflammatory drugs: an investigation using diclofenac in patients undergoing transurethral resection of the prostate. Eur J Anaesthesiol. 1987 Nov;4(6):429-34.; Wierod FS, Frandsen NJ, Jacobsen JD, et al. Risk of haemorrhage from transurethral prostatectomy in acetylsalicylic acid and NSAID-treated patients. Scand J Urol Nephrol. 1998 Apr;32(2): 120-2. doi:10.1080/003655998750014495; Nikanne E, Kokki H, Salo J, Linna TJ. Celecoxib and ketoprofen for pain management during tonsillectomy: a placebo-controlled clinical trial. Otolaryngol Head Neck Surg. 2005 Feb;132(2):287-94. doi:10.1016/j.otohns.2004.09.005; Moiniche S, Romsing J, Dahl JB, Tramrr MR. Nonsteroidal antiinflammatory drugs and the risk of operative site bleeding after tonsillectomy: A quantitative systematic review. Anesth Analg. 2003 Jan;96(1):68-77. doi:10.1213/00000539-200301000-00015; Forrest JB, Camu F, Greer IA, et al. Ketorolac, diclofenac, and ketoprofen are equally safe for pain re-lief after major surgery. Br J Anaesth. 2002 Feb;88(2):227-33. doi:10.1093/bja/88.2.227; Deutsch D, Boustiere C, Ferrari E, et al. Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Therap Adv Gastroenterol. 2017 Jun;10(6):495-505. doi:10.1177/1756283X17702092. Epub 2017 Apr 17.; Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol. 2017 Mar 21;23(11):1954-63. doi:10.3748/ wjg.v23.i11.1954; Мороз ЕВ, Каратеев АЕ, Крюков ЕВ, Чернецов ВА. Желудочно-кишечные кровотечения при использовании новых пероральных антикоагулянтов: эпидемиология, факторы риска, лечение и профилактика. Научно-практическая ревматология. 2017;55(6):675-84 [Moroz EV, Karateev AE, Kryukov EV, Chernetsov VA. Gastrointestinal bleeding with the use of new oral anticoagulants: epidemiology, risk factors, treatment, and prevention. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):675-684 (In Russ.)]. doi:10.14412/1995-4484-2017-675-684; Elia N, Lysakowski C, Tramer MR. Does Multimodal Analgesia with Acetaminophen, Non-steroidal Antiinflammatory Drugs, or Selective Cyclooxygenase-2 Inhibitors and Patient-controlled Analgesia Morphine Offer Advantages over Morphine Alone?: Meta-analyses of Randomized Trials. Anesthesiology. 2005 Dec;103(6):1296-304. doi:10.1097/00000542-200512000-00025; Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory druginduced hepatoxicity. Clin Liver Dis. 2013 Nov;17(4):643-56, ix. doi:10.1016/j.cld.2013.07.009. Epub 2013 Sep 4.; Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol. 2010 Dec 7;16(45):5651-61. doi:10.3748/wjg.v16.i45.5651; Laine L, Goldkind L, Curtis SP, et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol. 2009 Feb;104(2):356-62. doi:10.1038/ajg.2008.149. Epub 2009 Jan 27.; Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in patient treated with COX-2 selective inhibitors or nonselective NSAIDs: A case/noncase analysis of spontaneous reports. Clin Ther. 2006 Aug;28(8):1123-32. doi:10.1016/j.clinthera.2006.08.014; Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal antiinflammatory drugs. BMJ. 2003 Jul 5;327(7405):18-22. doi:10.1136/bmj.327.7405.18; Donati M, Conforti A, Lenti MC, et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol. 2016 Jul;82(1):238-48. doi:10.1111/bcp.12938. Epub 2016 Apr 27.; Gulmez SE, Larrey D, Pageaux GP, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013 Feb;36(2):135-44. doi:10.1007/s40264-012-0013-7; Каратеев АЕ. Российский опыт применения нимесулида: обзор клинических испытаний. Consilium medicum. 2011; 13(9):89-95 [Karateev AE. Russian experience of nimesulide: review of clinical trials. Consilium medicum. 2011;13(9): 89-95 (In Russ.)].; Каратеев АЕ, Журавлева МВ. Анализ спонтанных сообщений российских врачей о неблагоприятных реакциях, возникших на фоне приема нимесулида: гепатотоксические осложнения очень редки. Эффективная фармакотерапия. 2015;(8):4-12 [Karateev AE, Zhuravleva MV. Analysis of spontaneous Russian doctors about the adverse reactions that occurred in patients receiving nimesulide: hepatotoxic complications are very rare. Effektivnaya Farmakoterapiya. 2015;(8):4-12 (In Russ.)].; Andres E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol. 2008 Jan;15(1):15-21. doi:10.1097/MOH.0b013e3282f15fb9; Hamerschlak N, Cavalcanti AB. Neutropenia, agranulocytosis and dipyrone. Sao Paulo Med J. 2005 Sep 1;123(5):247-9. doi:10.1590/S1516-31802005000500009 Epub 2005 Dec 8.; Mourad AA, Bahna S. Hypersensitivities to non-steroidal antiinflammatory drugs. Expert Rev Clin Immunol. 2014 Sep;10(9): 1263-8. doi:10.1586/1744666X.2014.946905. Epub 2014 Aug 4.; Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013 Oct;68(10):1219-32. doi:10.1111/all.12260. Epub 2013 Oct 5.; White AA, Stevenson DD. Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization. Semin Respir Crit Care Med. 2012 Dec;33(6):588-94. doi:10.1055/s-0032-1325618. Epub 2012 Oct 9.; Simon RA. Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24. doi:10.1007/s11882-004-0037-x; Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15 Suppl 3:S2. doi:10.1186/ar4174. Epub 2013 Jul 24.; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31;382(9894):769-79. doi:10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.; Chinese Rheumatism Data Center; Chinese Systemic Lupus Erythematosus Treatment and Research Group. Recommendation for the prevention and treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications. Zhonghua Nei Ke Za Zhi. 2017 Jan 1;56(1):81-5. doi:10.3760/cma.j.issn.0578-1426.2017.01.021; Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011 May;70(5):818-22. doi:10.1136/ard.2010. 128660. Epub 2010 Sep 10.; Singh G, Triadafilopoulos S. Appropriative choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract. 2005 Oct;59(10):1210-7. doi:10.1111/j.1368-5031.2005.00660.x; Lanas A, Tornero J, Zamorano JL. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis. 2010 Aug;69(8): 1453-8. doi:10.1136/ard.2009.123166. Epub 2010 May 24.; Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report Gut. 2017 Jan;66(1):6-30. doi:10.1136/gutjnl2016-312288. Epub 2016 Oct 5.; Huang J, Sridhar S, Hunt R. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14-22. doi:10.1016/ S0140-6736(02)07273-2; Sostres C, Carrera-Lasfuentes P, Benito R, et al. Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users. Am J Gastroenterol. 2015 May;110(5):684-9. doi:10.1038/ajg.2015.98. Epub 2015 Apr 21.; Conroy RM, Pyorala K, Fitzgerald AP, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 Jun;24(11):987-1003. doi:10.1016/S0195-668X(03)00114-3; Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016 Jul;23(11):NP1-NP96. doi:10.1177/2047487316653709. Epub 2016 Jun 27.; Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017 Jan;76(1):17-28. doi:10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3.; Moore A, Makinson G, Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther. 2013 Jan 8;15(1):R6. doi:10.1186/ar4134; Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010 Jul 17; 376(9736):173-9. doi:10.1016/S0140-6736(10)60673-3. Epub 2010 Jun 16.; Chan FKL, Ching JYL, Tse YK, et al. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet. 2017 Jun 17;389(10087):2375-82. doi:10.1016/S0140-6736(17)30981-9. Epub 2017 Apr 11.; Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi:10.2165/ 11633470-000000000-00000; Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A metaanalysis. PLoS One. 2018 Jan 10;13(1):e0190798. doi:10.1371/ journal.pone.0190798. eCollection 2018.; Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007 Feb 10;369(9560):465-73. doi:10.1016/S0140-6736(07)60234-7; Laine L, Curtis SP, Langman M, et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008 Nov;135(5):1517-25. doi:10.1053/j.gastro.2008.07.067. Epub 2008 Aug 3.; Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med. 1999;107:48-54. doi:10.1016/S0002-9343(99) 00367-8; Yang M, Wang HT, Zhao M, et al. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury. Medicine (Baltimore). 2015 Oct;94(40):e1592. doi:10.1097/MD. 0000000000001592; Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular tromboembolic complications with meloxicam. Am J Med. 2004 Jul 15;117(2):100-6. doi:10.1016/j.amjmed.2004.03.012; Castellsague J, Pisa F, Rosolen V, et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf. 2013 Apr;22(4):365-75. doi:10.1002/pds.3385; Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78. doi:10.2165/00003495-200161090-00012; Каратеев АЕ, Цурган АВ. Ацеклофенак: опыт российских исследований. Современная ревматология. 2017;11(4):89-94 [Karateev AE, Tsurgan AV. Aceclofenac: the experience of Russian studies. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2017;11(4):89-94 (In Russ.)]. doi:10.14412/1996-7012-2017-4-89-94; Walker C, Biasucci LM. Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited. Postgrad Med. 2018 Jan; 130(1):55-71. doi:10.1080/00325481.2018.1412799. Epub 2017 Dec 15.; Tacconelli S, Bruno A, Grande R, et al. Nonsteroidal antiinflammatory drugs and cardiovascular safety – translating pharmacological data into clinical readouts. Expert Opin Drug Saf. 2017 Jul;16(7):791-807. doi:10.1080/14740338.2017.1338272. Epub 2017 Jun 8.; Antman EM. Evaluating the Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs. Circulation. 2017 May 23;135(21):2062-72. doi:10.1161/CIRCULATIONAHA.117. 027288; Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011 Jan 11;342:c7086. doi:10.1136/bmj.c7086; Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Safety. 2013;22:559-70. doi.org/10.1002/pds.3437; Eisner F, Hermann D, Bajaeifer K, et al. Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience. Visc Med. 2017 Jun;33(3):221-6. doi:10.1159/000475450. Epub 2017 Jun 16.; Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017 Mar;152(4):706-15. doi:10.1053/j.gastro.2017.01.031; Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017 Jan 15;11(1):27-37. doi:10.5009/gnl15502; Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016 Nov 9;14(1):179. doi:10.1186/s12916-016-0718-z; Gargallo CJ, Sostres C, Lanas A. Prevention and Treatment of NSAID Gastropathy. Curr Treat Options Gastroenterol. 2014 Dec; 12(4):398-413. doi:10.1007/s11938-014-0029-4; Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S5. doi:10.1186/ar4177. Epub 2013 Jul 24.; Yang M, He M, Zhao M, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin. 2017 Jun;33(6):973-80. doi:10.1080/03007995.2017.1281110. Epub 2017 Jan 25.; Spiegel BM, Farid M, Dulai GS, et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med. 2006 May;119(5):448.e27-36. doi:10.1016/j.amjmed.2005.11.020; Каратеев АЕ. Шесть ножей в спину ингибиторам протонной помпы. Научно-практическая ревматология. 2013;51(3):332-40 [Karateev AE. Six stabs in the back of proton pump inhibitors. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):332-40 (In Russ.)]. doi:10.14412/1995-4484-2013-1509; Maes ML, Fixen DR, Linnebur SA. Adverse effects of protonpump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017 Sep;8(9):273-97. doi:10.1177/20420986 17715381. Epub 2017 Jun 29.; Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):697-710. doi:10.1038/ nrgastro.2017.117. Epub 2017 Sep 20.; Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014 Apr; 37(4):201-11. doi:10.1007/s40264-014-0144-0; Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. doi:10.1038/clpt.2010.219; Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012 Sep;40(9):1698-711. doi:10.1124/dmd.112.045575. Epub 2012 May 30.; Ohbuchi M, Noguchi K, Kawamura A, Usui T. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica. 2012 Jul;42(7):633-40. doi:10.3109/ 00498254.2011.653655. Epub 2012 Feb 7.; Neubauer H, Engelhardt A, Krü ger JC, et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel – a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol. 2010 Jul;56(1):91-7. doi:10.1097/FJC.0b013e3181e19739; Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9): 937-44. doi:10.1001/jama.2009.261; Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-8. doi:10.1503/cmaj.082001; Johnson DA, Chilton R, Liker HR. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling. Postgrad Med. 2014 May;126(3):239-45. doi:10.3810/pgm.2014. 05.2772; Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcer by esomeprazole in at-risk patients using non-selective NSAIDs or COX-2 inhibitor. Am J Gastroenterol. 2006 Apr;101(4):701-10. doi:10.1111/j.1572-0241.2006.00499.x Epub 2006 Feb 22.; Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a pro-ton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a doubleblind, randomised trial. Lancet. 2007 May 12;369(9573):1621-6. doi:10.1016/S0140-6736(07)60749-1; Tang CL, Ye F, Liu W, et al. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a meta-analysis. Helicobacter. 2012;17:286-96. doi:10.1111/j.1523-5378.2012.00942.x; Ивашкин ВТ, Маев ИВ, Лапина ТЛ и др. Лечение инфекции Helicobacter pylori: мейнстрим и новации (Обзор литературы и резолюция Экспертного совета Российской гастроэнтерологической ассоциации 19 мая 2017 г.). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(4):4-21 [Ivashkin VT, Maev IV, Lapina TL, et al. Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and the resolution of the Expert Council of the Russian Gastroenterological Association on May 19, 2017). Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2017;27(4):4-21 (In Russ.)].; Tai FWD, McAlindon ME. NSAIDs and the small bowel. Curr Opin Gastroenterol. 2018 May;34(3):175-82. doi:10.1097/MOG. 0000000000000427; Washio E, Esaki M, Maehata Y, et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory DrugInduced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2016 Jun;14(6):809-15.e1. doi:10.1016/j.cgh.2015.10.022. Epub 2015 Oct 30.; Syer SD, Blackler RW, Martin R, et al. NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol. 2015 Apr; 50(4):387-93. doi:10.1007/s00535-014-1032-1. Epub 2015 Jan 10.; Lee JH, Lee YC, Jeon SW, et al. Guidelines of prevention and treatment for NSAID-related peptic ulcers. Korean J Gastroenterol. 2009;54:309-17. doi:10.4166/kjg.2009.54.5.309; Iijima K, Ichikawa T, Okada S, et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci. 2009;54:1500-7. doi:10.1007/s10620-008-0507-4; Мороз ЕВ, Каратеев АЕ. Ребамипид: эффективная медикаментозная профилактика НПВП-энтеропатии возможна. Современная ревматология. 2016;10(4):97-105 [Moroz EV, Karateev AE. Rebamipide: Effective drug prevention of NSAID enteropathy is possible. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(4):97-105 (In Russ.)]. doi:10.14412/1996-7012-2016-4-97-105; Jaafar MH, Safi SZ, Tan MP, et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2017 Dec 1. doi:10.1007/s10620-017-4871-9 [Epub ahead of print].; Hasegawa M, Horiki N, Tanaka K, et al. The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group. Mod Rheumatol. 2013 Nov;23(6):1172-8. doi:10.1007/s10165-012-0819-2. Epub 2013 Jan 10.; Park SH, Cho CS, Lee OY, et al. Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled TrialSTORM STUDY. J Clin Biochem Nutr. 2007 Mar;40(2):148-55. doi:10.3164/jcbn.40.148; Kim JH, Park SH, Cho CS, et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity. Gut Liver. 2014 Jul;8(4):371-9. doi:10.5009/gnl. 2014.8.4.371. Epub 2013 Dec 24.; Kurokawa S, Katsuki S, Fujita T, et al. A randomized, doubleblinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol. 2014 Feb;49(2):239-44. doi:10.1007/s00535-013-0805-2. Epub 2013 Apr 18.; Watanabe T, Takeuchi T, Handa O, et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-tosevere small intestinal damage. PLoS One. 2015 Apr 15;10(4): e0122330. doi:10.1371/journal.pone.0122330. eCollection 2015.; Zhang S, Qing Q, Bai Y, et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013 Jul;58(7):1991-2000. doi:10.1007/s10620-013-2606-0. Epub 2013 Feb 28.; Yokoyama H, Ito N, Soeda S, et al. Influence of non-steroidal anti-inflammatory drugs on antiplatelet effect of aspirin. J Clin Pharm Ther. 2013 Feb;38(1):12-5. doi:10.1111/j.1365-2710.2012. 01373.x. Epub 2012 Aug 6.; Hohlfeld T, Saxena A, Schrör K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs – pharmacological mechanisms and clinical relevance. Thromb Haemost. 2013 May;109(5):825-33. doi:10.1160/TH12-07-0532. Epub 2012 Dec 13.; Meek IL, Vonkeman HE, Kasemier J, et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013 Mar;69(3):365-71. doi:10.1007/s00228-012-1370-y. Epub 2012 Aug 14.; Strand V. Are COX-2 inhibitors preferable to non-selective nonsteroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007 Dec 22;370(9605):2138-51. doi:10.1016/S0140-6736(07)61909-6; Группа экспертов под председательством С.А. Бойцова и Н.В. Погосова. Российское кардиологическое общество. Национальное общество профилактической кардиологии. Российское общество профилактики неинфекционных заболеваний. Кардиоваскулярная профилактика 2017. Доступно по ссылке: http://ropniz.ru/wp-content/uploads/2017/11/CVP_2017. pdf [A panel of experts chaired by S.A. Boytsov and N.V. Pogosov. Russian Cardiology Society. National Society of Preventive Cardiology. Russian Society for the Prevention of Noncommunicable Diseases. Cardiovascular prevention 2017. Available from: http://ropniz.ru/wp-content/uploads/2017/ 11/CVP_2017.pdf].; Carey RM, Whelton PK; 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med. 2018 Mar 6;168(5):351-8. doi:10.7326/M17-3203. Epub 2018 Jan 23.; Рабочая группа членов Правления Научного общества нефрологов России под руководством А.В. Смирнова. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Санкт-Петербург: Левша; 2012. 51 с. [Working group of members of the Board of the Scientific Society of Nephrologists of Russia under the guidance of A.V. Smirnova. National recommendations. Chronic kidney disease: the basic principles of screening, diagnosis, prevention, and approaches to treatment. St. Petersburg: Levsha; 2012. 51 p.]. ISBN 978-5-93356-129-3; Рабочая группа под руководством Денисова И.Н. Общероссийская общественная организация «Ассоциация врачей общей практики (семейных врачей) Российской Федерации» Хроническая болезнь почек. Клинические рекомендации. Москва; 2014. Доступно по ссылке: http://sevgb6.ru/doc/ klinicheskie-rekomendacii/hbp.pdf [The working group, led by Denisov I.N. All-Russian Public Organization «Association of General Practitioners (Family Physicians) of the Russian Federation» Chronic kidney disease. Clinical recommendations. Moscow; 2014. Available from: http://sevgb6.ru/doc/klinicheskierekomendacii/hbp.pdf].; Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013 Jun 4; 158(11):825-30. doi:10.7326/0003-4819-158-11-201306040-00007; National Institute for Health and Care Excelence (NICE): Chronic kidney disease in adults: assessment and management. Available at: https://www.nice.org.uk/guidance/cg182 Accessed September 26th 2017.

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2536
https://doi.org/10.14412/1995-4484-2018-1-29

Destabilized hypertension as a complication of therapy with nonsteroidal anti-inflammatory drugs: the importance of the problem ; Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы

Συγγραφείς: A. E. Karateev, А. Е. Каратеев

Πηγή: Modern Rheumatology Journal; Том 12, № 2 (2018); 64-72 ; Современная ревматология; Том 12, № 2 (2018); 64-72 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2018-2

Θεματικοί όροι: антигипертензивная терапия, complications, hypertension, cardiovascular events, antihypertensive therapy, осложнения, артериальная гипертензия, кардиоваскулярные осложнения

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/827/797; Каратеев АЕ. Проект национальных клинических рекомендаций (основные положения). Рациональное использование нестероидных противовоспалительных препаратов по результатам совещания группы экспертов, Москва, 01.04.2017. Научно-практическая ревматология. 2017;55(4):452-6. [Karateev AE. Draft national clinical guidelines (general provisions). Rational use of nonsteroidal antiinflammatory drugs. According to the results of the expert group meeting, Moscow, 01.04.2017. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017;55(4):452-6. (In Russ.)]. doi:10.14412/ 1995-4484-2017-452-456; Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015 Mar 19;13:55. doi:10.1186/s12916-015-0285-8.; Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013; 16(5):821-47.; Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):43-50. doi:10.1002/pds.3463. Epub 2013 May 30.; Sarganas G, Buttery AK, Zhuang W, et al. Prevalence, trends, patterns and associations of analgesic use in Germany. BMC Pharmacol Toxicol. 2015 Oct 1;16:28. doi:10.1186/s40360-015-0028-7.; Wang P, Avorn J, Brookhart M, et al. Effects of noncardiovascular comorbidities on anti-hypertensive use in elderly hypertensives. Hypertension. 2005 Aug;46(2):273-9. Epub 2005 Jun 27.; Каратеев АЕ, Попкова ТВ, Новикова ДС и др. Оценка риска желудочно-кишечных и сердечно-сосудистых осложнений, ассоциированных с приемом нестероидных противовоспалительных препаратов в популяции СНГ: предварительные данные эпидемиологического исследования КОРОНА-2. Научно-практическая ревматология. 2014;52(6):600–6. [Karateev AE, Popkova TV, Novikova DS, et al. Assessment of risk for gastrointestinal and cardiovascular complications associated with the use of nonsteroidal anti-inflammatory drugs in the cis population: preliminary data of the CORONA-2 epidemiological survey. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(6):600–6. (In Russ.)]. doi:10.14412/ 1995-4484-2014-600-606; Чазова ИЕ, Жернакова ЮВ, Ощепкова ЕВ и др. Распространенность факторов риска развития сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014;(10):4-12. [Chazova IE, Zhernakova YuV, Oshchepkova EV, et al. Prevalence of cardiovascular risk factors in the Russian population of patients with arterial hypertension. Kardiologiya. 2014;(10): 4-12. (In Russ.)].; Здравоохранение в России. Статистический сборник. Москва: Росстат; 2017. 170 с. [Zdravookhranenie v Rossii. Statisticheskii sbornik [Healthcare in Russia. Statistical compendium]. Moscow: Rosstat; 2017. 170 p.]; Reboussin DM, Allen NB, Griswold ME, et al. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA /ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017 Nov 7. pii: S0735-1097(17) 41517-8. doi:10.1016/j.jacc.2017.11.004. [Epub ahead of print]; Lovell AR, Ernst ME. Drug-Induced Hypertension: Focus on Mechanisms and Management. Curr Hypertens Rep. 2017 May; 19(5):39. doi:10.1007/s11906-017-0736-z.; Salort-Llorca C, Minguez-Serra MP, Silvestre-Donat FJ. Interactions between ibuprofen and antihypertensive drugs: incidence and clinical relevance in dental practice. Med Oral Patol Oral Cir Bucal. 2008 Nov 1;13(11):E717-21.; Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993 Feb 22;153(4):477-84.; Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol. 2018 Feb 21. doi:10.1111/bph.14167. [Epub ahead of print]; Harris C, Breyer M. Update on Cyclooxygenase-2 Inhibitors. Clin J Am Soc Nephrol. 2006 Mar;1(2):236-45. Epub 2006 Feb 1.; Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension. 2004 Mar;43(3):525-30. Epub 2004 Jan 19.; Singh G, Miller JD, Lee FH, et al. Pevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination survey. Am J Manag Care. 2002 Oct;8(15 Suppl):S383-91.; Harley C, Wagner S. The prevalence of cardiovascular risk factors in parients prescribing anti-inflammatory drugs; data from managed care. Clin Ther. 2003 Jan;25(1):139-49.; Curhan G, Willet W, Rosner B, Stampfer M. Frequency оf analgestic use and risk of hypertension in younger woman. Arch Intern Med. 2002 Oct 28;162(19):2204-8.; Formam J, Stampfer M, Curhan G. Nonnarcotic analgetic dose and risk of incident hypertension in US women. Hypertension. 2005 Sep;46(3):500-7. Epub 2005 Aug 15.; Solomon D, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004 Aug;44(2):140-5. Epub 2004 Jun 28.; Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006 Sep 5;114(10):1028-35.; Silverstein F, Faich G, Goldstein J, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA. 2000 Sep 13;284(10):1247-55.; Singh G, Fort J, Goldstein J, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med. 2006 Mar;119(3):255-66.; Cannon C, Curtis S, FitzGerald G, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov 18;368(9549): 1771-81.; Sowers J, White W, Pitt B, et al. The effects of cycloxygenase -2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-houar blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005 Jan 24;165(2):161-8.; Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519-29. doi:10.1056/NEJMoa1611593. Epub 2016 Nov 13.; Ruschitzka F, Borer JS, Krum H, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017 Nov 21; 38(44):3282-3292. doi:10.1093/eurheartj/ehx508.; White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007 Jan 1; 99(1):91-8. Epub 2006 Nov 10.; Elliott WJ. Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality? Curr Hypertens Rep. 2010 Aug;12(4):258-66. doi:10.1007/s11906-010-0120-8.; Krum H, Swergold G, Curtis SP, et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009 Apr;27(4):886-93. doi:10.1097/HJH.0b013e328325d831.; Aw T, Haas S, Liew D, Krum H. Metaanalysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005 Mar 14;165(5):490-6. Epub 2005 Feb 14.; Chan C, Reid C, Aw T, et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009 Dec;27(12):2332-41. doi:10.1097/HJH. 0b013e3283310dc9.; Curtis SP, Ng J, Yu Q, et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther. 2004 Jan;26(1):70-83.; Bingham CO, Sebba AI, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford). 2007 Mar;46(3):496-507. Epub 2006 Aug 27.; Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and activecomparator controlled 12-week efficacy trial. Curr Med Res Opin. 2002;18(2):49-58.; Matsumoto AK, Melian A, Mandel DR, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002 Aug;29(8):1623-30.; Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. 2004 Feb;50(2):598-606.; Dong YH, Chang CH, Wu LC, et al. Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study. Br J Clin Pharmacol. 2018 Feb 22. doi:10.1111/bcp.13537. [Epub ahead of print]; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Lancet. 2013 Aug 31;382(9894):769-79. doi:10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.; Gunter BR, Butler KA, Wallace R, et al. Non-steroidal anti-inflammatory druginduced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther. 2017 Feb;42(1):27-38. doi:10.1111/jcpt.12484. Epub 2016 Dec 26.; Bally M, Dendukuri, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017 May 9;357: j1909. doi:10.1136/bmj.j1909.; Brown J, Dollery C, Valdes G. Interaction of nonsteroidal antiinflammatory drugs with antihypertensove and diuretic agents. Am J Med. 1986 Aug 25;81(2B):43-57.; Durao V, Martins Prata M, Pires-Goncalves LM. Modification of antihypertensive effect of beta-adrenoreceptorblocking agents by inhibition of endogenous prostaglandin synthesis. Lancet 1977;12: 1005-1007.; Oates JA. Antagonism of antihypertensive drug therapy by non-steroidal anti-inflammatory drugs. Hypertension. 1988 Mar;11(3 Pt 2): II4-6.; Quilley J, Duchin K, Hudes E, McGiff J. The antihypertensive effect of captopril in essential hypertension. Relationship to prostaglandins and kallikrein-kinin system. J Hypertens. 1987 Feb;5(1):121-8.; Salvetti A, Pedrinalli R, Magagna A, Ugenti P. Differential effects of selective and non-selective prostaglandin-synthesis inhibition on pharmacological response to captopril in patients with essential hypertension. Clin. Sci. 1982;63:261-3.; Watkins J, Abbott E, Hensby C, et al. Attenuation of hypotensive effect of propranalol and thiaside diuretics by indomethacin. Br Med J. 1980 Sep 13;281(6242): 702-5.; Polonia J, Boaventure J, Gama G, et al. Influence of nonsteroidal antiinflammatory drugs on renal function and 24-hour blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens. 1995 Aug;13(8):925-31.; Wong D, Spence J, Lamki L, et al. Effect of nonsteroidal antiinflammatory drugs on control of hypertension of beta-blockers and diuretics. Lancet. 1986 May 3;1(8488): 997-1001.; Baez M, Alvarez C, Weilder D. Effects of the non-steroidal anti-inflammatory drugs, piroxicam or sulindac, on the antihypertensive action of propranolol and verapamil. J Hypertens Suppl. 1987 Dec;5(5):S563-6.; Cinquegrani M, Liang C. Antihypertensive effects of pinacidil in patients with and without indomethacin pretreatment. Clin Exp Hypertens A. 1988;10(3): 411-31.; Hardy B, Bartle W, Myers M, et al. Effects of indomethacin on the pharmaсokinetics of felodipine. Br J Clin Pharmacol. 1988 Nov;26(5):557-62.; Houston M, Weir M, Gray J, et al. The effects of non-steroidal antiinflammatory drugs on blood pressure of patients with hypertension controlled by verapamil. Arch Intern Med. 1995 May 22;155(10):1049-54.; Klassen D, Goadfriend T, Schuma A, et al. Assesment of Blood pressure during treatment with naproxen of ibuprofen in hypertensive patients treated with hydrochlorthiazide. J Clin Pharmacol. 1993 Oct;33(10):971-8.; Johnson D, Hisel T, Phillips B. Effect of cyclooxygenase-2 inhibitors on blood pressure. Ann Pharmacother. 2003 Mar;37(3):442-6.; Whelton A, Fort J, Puma J, et al. SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001 Mar-Apr;8(2):85-95.; Whelton A, White W, Bello A, et al. SUCCESS VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥ 65 years of age with systolic hypertension and osteoarthritis. Am J Cardiol. 2002 Nov 1;90(9):959-63.; Dilger K, Herrlinger C, Peters J, et al. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol. 2002 Sep;42(9):985-94.; Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994 Aug 15;121(4):289-300.; Pavlicevic I, Kuzmanic M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008 Fall;15(3):e372-82. Epub 2008 Oct 24.; Aljadhey H, Tu W, Hansen RA, Blalock SJ, et al. Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovasc Disord. 2012 Oct 24;12:93. doi:10.1186/1471-2261-12-93.; Villa J, Cano A, Franco D3, et al. Clinical relevance of drug interactions between nonsteroidal antiinflammatory drugs (NSAIDs) and antihypertensives. [Article in Spanish]. Aten Primaria. 2014 Nov;46(9): 464-74. doi:10.1016/j.aprim.2013.11.010. Epub 2014 Mar 22.; Ljungman C, Kahan T, Schiö ler L, et al. Non-steroidal anti-inflammatory drugs and blood pressure control in patients treated for hypertension: results from the Swedish primary care cardiovascular database. Blood Press. 2017 Aug;26(4):220-228. doi:10.1080/ 08037051.2017.1290503. Epub 2017 Feb 13.; Ruff CT, Morrow DA, Jarolim P, et al. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. J Rheumatol. 2011 Jun;38(6):1071-8. doi:10.3899/jrheum.100880. Epub 2011 Apr 1.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/827
https://doi.org/10.14412/1996-7012-2018-2-64-72

NEW DATA ON THE SAFETY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: THE CONCEPT OF THE HIGH CLASS-SPECIFIC CARDIOVASCULAR RISK OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS IS OUTDATED ; Новые данные, касающиеся безопасности нестероидных противовоспалительных препаратов: представление о «класс-специфическом» высоком кардиоваскулярном риске селективных ингибиторов циклооксигеназы 2 устарело

Συγγραφείς: A. E. Karateev, D. S. Novikova, E. L. Nasonov, А. Е. Каратеев, Д. С. Новикова, Е. Л. Насонов

Πηγή: Rheumatology Science and Practice; Vol 55, No 2 (2017); 218-223 ; Научно-практическая ревматология; Vol 55, No 2 (2017); 218-223 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20172

Θεματικοί όροι: PRECISION, celecoxib, naproxen, ibuprofen, safety, cardiovascular events, целекоксиб, напроксен, ибупрофен, безопасность, кардиоваскулярные осложнения

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2366/1569; Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-23 [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(1):4-23 (In Russ.)]. doi:10.14412/1996-7012-2015-1-4-23; Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015 Mar 19;13:55. doi:10.1186/s12916-015-0285-8; Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015 Feb 20;8:105-18. doi:10.2147/JPR.S75160. eCollection 2015.; [No authors listed]. NSAIDs and serious cardiovascular disorders: especially COX-2 inhibitors and diclofenac. Prescrire Int. 2016 Jan;25(167):14-6.; Katz JA. COX-2 inhibition: what we learned – a controversial update on safety data. Pain Med. 2013 Dec;14 Suppl 1:S29-34. doi:10.1111/pme.12252; Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007;42:3-27. doi:10.1007/1-4020-5688-5_1; Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011 May;70(5):818-22. doi:10.1136/ard.2010.128660. Epub 2010 Sep 10.; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Lancet. 2013 Aug 31;382(9894):769-79. doi:10.1016/S0140- 6736(13)60900-9. Epub 2013 May 30.; Xu C, Gu K, Yasen Y, Hou Y. Efficacy and safety of celecoxib therapy in osteoarthritis: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016 May;95(20):e3585. doi:10.1097/MD.0000000000003585; Moore A, Makinson G, Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther. 2013 Jan 8;15(1):R6. doi:10.1186/ar4134; Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi:10.2165/11633470-000000000-00000; Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:7086. doi:10.1136/bmj.c7086; Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Safety. 2013;22:559-70. doi:10.1002/pds.3437; Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006 Oct 4;296(13):1619-32. doi:10.1001/jama.296.13.jrv60015. Epub 2006 Sep 12.; Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal antiinflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi:10.1136/bmj.i4857; Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519-29. doi:10.1056/NEJMoa1611593. Epub 2016 Nov 13.; Becker MC, Wang TH, Wisniewski L, et al. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009 Apr;157(4):606- 12. doi:10.1016/j.ahj.2008.12.014. Epub 2009 Feb 25.; Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov 18;368(9549):1771-81. doi:10.1016/S0140-6736(06)69666-9; Krum H, Swergold G, Curtis SP, et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009 Apr;27(4):886-93. doi:10.1097/HJH.0b013e328325d831; Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007 Feb 10;369(9560):465-73. doi:10.1016/S0140-6736(07)60234-7

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2366
https://doi.org/10.14412/1995-4484-2017-218-223

ПОВЫШЕННАЯ ВЯЗКОСТЬ КРОВИ – ОДИН ИЗ ФАКТОРОВ РАЗВИТИЯ КАРДИОВАСКУЛЯРНЫХ ОСЛОЖНЕНИЙ У БОЛЬНЫХ С ИСТИННОЙ ПОЛИЦИТЕМИЕЙ

Θεματικοί όροι: 2. Zero hunger, thrombotic complications, кардиоваскулярные осложнения, polycythemia vera (erythremia, Vaquez-Osler disease), cardiovascular complications, болезнь Вакеза-Ослера), тромботические осложнения, 3. Good health, истинная полицитемия (эритремия

Σύνδεσμος πρόσβασης: https://research-journal.org/medical/povyshennaya-vyazkost-krovi-odin-iz-faktorov-razvitiya-kardiovaskulyarnyx-oslozhnenij-u-bolnyx-s-istinnoj-policitemiej/
https://research-journal.org/wp-content/uploads/2011/10/2-1-68.pdf#page=23
https://cyberleninka.ru/article/n/povyshennaya-vyazkost-krovi-odin-iz-faktorov-razvitiya-kardiovaskulyarnyh-oslozhneniy-u-bolnyh-s-istinnoy-politsitemiey

CARDIOVASCULAR COMPLICATIONS IN BREAST CANCER TREATMENT

Συγγραφείς: O. M. Magomedov, P. O. Magomedova, G. M. Magomedov

Πηγή: Российский кардиологический журнал, Vol 0, Iss 1, Pp 73-76 (2010)

Θεματικοί όροι: рак молочной железы, методы лечения, кардиоваскулярные осложнения, смертность, Diseases of the circulatory (Cardiovascular) system, RC666-701

Περιγραφή αρχείου: electronic resource

Relation: https://russjcardiol.elpub.ru/jour/article/view/1424; https://doaj.org/toc/1560-4071; https://doaj.org/toc/2618-7620

Σύνδεσμος πρόσβασης: https://doaj.org/article/c2ccb0351fc2431da29642154b4bc2e3

Naproxen: A universal analgesic with a minimal risk of cardiovascular events ; Напроксен: универсальный анальгет и к с минимальным риском кардиоваскулярных осложнений

Συγγραφείς: A. E. Karateev, А. Е. Каратеев

Πηγή: Modern Rheumatology Journal; Том 10, № 2 (2016); 70-77 ; Современная ревматология; Том 10, № 2 (2016); 70-77 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2016-2

Θεματικοί όροι: ингибиторы протонной помпы, NSAID gastropathy, cardiovascular events, prevention, naproxen, proton pump inhibitors, НПВП-гастропатия, кардиоваскулярные осложнения, профилактика, напроксен

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/687/672; Яхно НН, Кукушкин МЛ, редакторы. Боль: практическое руководство для врачей. Москва: Издательство РАМН; 2012. 512 c. [Yakhno NN, Kukushkin ML, editors. Bol' (prakticheskoe rukovodstvo dlya vrachei) [Pain (practical guide for physicians)]. Moscow: Izdatel'stvo RAMN; 2012. 512 p.]; Насонов ЕЛ. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой. Клиническая фармакология и терапия. 2003;12(1):64-9. [Nasonov EL. Analgesic therapy in rheumatology: a journey between Scylla and Charybdis. Klinicheskaya Farmakologiya i Terapiya. 2003;12(1):64-9. (In Russ.)].; Lee YC. Effect and treatment of chronic pain in inflammatory arthritis. Curr Rheumatol Rep. 2013 Jan;15(1):300. doi:10.1007/s11926-012-0300-4.; van de Laar M, Pergolizzi J, Mellinghoff H, et al. Pain Treatment in Arthritis-Related Pain: Beyond NSAIDs. Open Rheumatol J. 2012;6:320-30. doi:10.2174/1874312901206010320. Epub 2012 Dec 13.; Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-24. [Karateev AE, Nasonov EL, Yakhno NN et al. Clinical guidelines «Rational use of nonsteroidal antiinflammatory drugs (NSAIDs) in clinical practice». Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(1):4- 24. (In Russ.)]. DOI: http://dx.doi.org/10. 14412/1996-7012-2015-1-4-23; Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015 Mar 19;13:55. doi:10.1186/s12916-015-0285-8.; Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013;16(5):821-47.; Каратеев АЕ, Попкова ТВ, Новикова ДС и др. Оценка риска желудочно-кишечных и сердечно-сосудистых осложнений, ассоциированных с приемом нестероидных противовоспалительных препаратов в популяции СНГ: предварительные данные эпидемиологического исследования КОРОНА-2. Научно-практическая ревматология. 2014;52(6):600–6. [Karateev AE, Popkova TV, Novikova DS, et al. Assessment of risk for gastrointestinal and cardiovascular complications associated with the use of nonsteroidal anti-inflammatory drugs in the CIS population: preliminary data of the CORONA-2 epidemiological survey. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(6):600–6. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2014-600-606; Capone M, Tacconelli S, Sciulli M, et al. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther. 2007 Aug;322(2): 453-60. Epub 2007 May 1.; McGettigan P, Henry D. Use of Non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle- and high- income countries. PLoS Med. 2013;10(2):e1001388. doi:10.1371/journal.pmed.1001388. Epub 2013 Feb 12.; Runkel R, Chaplin M, Boost G, et al. Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects. J Pharm Sci. 1972 May;61(5):703-8.; Aeidler H. Clinical results of a multicentral double-blind examination of naproxen compared to indomethacin in chronic rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis. Arzneimittelforschung. 1975 Feb;25(2A):315-8.; Bowers D, Dyer H, Fosdick W, et al. Naproxen in rheumatoid arthritis. A controlled trial. Ann Intern Med. 1975 Oct;83(4):470-5.; Clarke A. A Double-blind comparison of naproxen against indometacin in osteoarthrosis. Arzneimittelforschung. 1975 Feb;25(2A):302-4.; Castles J, Moore T, Vaughan J, et al. Multicenter comparison of naproxen and indomethacin in rheumatoid arthritis. Arch Intern Med. 1978 Mar;138(3):362-6.; Blechman W, Willkens R, Boncaldo G, et al. Naproxen in osteoarthrosis. Doubleblind crossover trial. Ann Rheum Dis. 1978 Feb;37(1):80-4.; Melton JW 3rd, Lussier A, Ward JR, et al. Naproxen vs. aspirin in osteoarthritis of the hip and knee. J Rheumatol. 1978 Fall;5(3):338-46.; Martinez-Lavin M, Holman K, Smyth C, Vaughan J. A comparison of naproxen, indomethacin and aspirin in osteoarthritis. J Rheumatol. 1980 Sep-Oct;7(5):711-6.; Bjö rkenheim J, Helland J, Peltonen J. A double-blind crossover evaluation of naproxen and piroxicam in osteoarthritis of hip or knee. J Int Med Res. 1985;13(5):263-9.; Dunn T, Clark V, Jones G. Preoperative oral naproxen for pain relief after day-case laparoscopic sterilization. Br J Anaesth. 1995 Jul;75(1):12-4.; Comfort V, Code W, Rooney M, Yip R. Naproxen premedication reduces postoperative tubal ligation pain. Can J Anaesth. 1992 Apr;39(4):349-52.; Code W, Yip R, Rooney M, et al. Preoperative naproxen sodium reduces postoperative pain following arthroscopic knee surgery. Can J Anaesth. 1994 Feb;41(2):98-101.; Malmstrom K, Kotey P, Coughlin H, Desjardins P. A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model. Clin J Pain. 2004 May-Jun;20(3):147-55.; Derry C, Derry S, Moore RA, McQuay HJ. Single dose oral naproxen and naproxen sodium for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004234. doi:10.1002/14651858.CD004234.pub3.; Simmons R, Owen S, Abbott C, et al. Naproxen sodium and paracetamol/dextropropoxyphene in sports injuries – a multicentre comparative study. Br J Sports Med. 1982 Jun;16(2):91-5.; Fathi M, Zare MA, Bahmani HR, Zehtabchi S. Comparison of oral oxycodone and naproxen in soft tissue injury pain control: a double-blind randomized clinical trial. Am J Emerg Med. 2015 Sep;33(9):1205-8. doi:10.1016/j.ajem.2015.05.021. Epub 2015 May 29.; Friedman BW, Dym AA, Davitt M, et al. Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. JAMA. 2015 Oct 20;314(15):1572-80. doi:10.1001/jama.2015.13043.; Sturge RA, Scott JT, Hamilton EB, et al. Multicentre trial of naproxen and phenylbutazone in acute gout. Ann Rheum Dis. 1977 Feb;36(1):80-2.; Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin. 1991;12(7):423-9.; Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008 May 31;371(9627):1854-60. doi:10.1016/S0140; Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology (Oxford). 2014 Nov;53(11):1920-6. doi:10.1093/rheumatology/keu157. Epub 2014 Apr 23.; Reginster J, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007 Jul;66(7):945-51. Epub 2006 Dec 1.; Singh G, Fort J, Goldstein J, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med. 2006 Mar;119(3):255-66.; Bombardier C, Laine L, Reicin A, et al. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528; Farkouh M, Kirshner H, Harrington R, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet. 2004 Aug 21-27;364(9435):675-84.; Moore RA, Moore OA, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010 Feb;69(2):374-9. doi:10.1136/ard.2009.107805. Epub 2009 Apr 12.; Song G, Seo Y, Kim J, et al. Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. J Rheumatol. 2016 Jan 14. [Epub ahead of print]; Kroon FP, van der Burg LR, Ramiro S, et al. Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review. J Rheumatol. 2016 Feb 1. pii: jrheum.150721. [Epub ahead of print]; Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014 Jan;73(1):101-7. doi:10.1136/annrheumdis-2012-203201. Epub 2013 May 21.; Collantes E, Curtis SP, Lee KW, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract. 2002 May 22;3:10.; Van Hecken A, Schwartz J, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.; Hinz B, Cheremina O, Besz D, et al. Impact of naproxen sodium at over-thecounter doses on cyclooxygenase isoforms in human volunteers. Int J Clin Pharmacol Ther. 2008 Apr;46(4):180-6.; Schiff M, Hochberg M, Oldenhof J, Brune K. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin. 2009 Oct;25(10):2471-7. doi:10.1185/030079 90903185706.; Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ. 2011 Jan 11;342:c7086. doi:10.1136/bmj.c7086.; Varas-Lorenzo С, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013 Jun;22(6):559-70.; Ray W, Varas-Lorenzo C, Chung C, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009 May;2(3):155-63. doi:10.1161/CIRCOUTCOMES. 108.805689. Epub 2009 May 5.; Gislason G, Rasmussen J, Abildstrom S, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009 Jan 26;169(2): 141-9. doi:10.1001/archinternmed.2008.525.; Roumie C, Choma N, Kaltenbach L, et al. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular eventsstroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1053-63. doi:10.1002/pds.1820.; Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015 Feb;23(1):1-16. doi:10.1007/s10787-014-0225-9. Epub 2014 Dec 17.; Antman E, Bennett J, Daugherty A, et al. Use of Nonsteroidal Antiinflammatory Drugs. An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation. 2007 Mar 27; 115(12):1634-42. Epub 2007 Feb 26.; Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal antiinflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011 May;70(5):818-22. doi:10.1136/ard.2010. 128660. Epub 2010 Sep 10.; Henry D, Lim L, Garcia Rodriguez L, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996 Jun 22; 312(7046):1563-6.; Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi:10.2165/11633470-000000000-00000.; Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAIDinduced mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S5. doi:10.1186/ar4177. Epub 2013 Jul 24.; Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015 Jan 22;7:31-41. doi:10.2147/DHPS.S71976.eCollection 2015.; Goldstein J, Hochberg M, Fort J, et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther. 2010 Aug;32(3):401-13. doi:10.1111/j.1365-2036.2010.04378.x. Epub 2010 May 22.; Sostek M, Fort J, Estborn L, et al. Longterm safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. Curr Med Res Opin. 2011 Apr;27(4):847-54. doi:10.1185/03007995.2011. 555756. Epub 2011 Feb 14.; Chang CC, Chiou CS, Lin HL, et al. Increased Risk of Acute Pancreatitis in Patients with Rheumatoid Arthritis: A Population-Based Cohort Study. PLoS One. 2015 Aug 11;10(8):e0135187. doi:10.1371/journal.pone.0135187. eCollection 2015.; Sorensen HT, Jacobsen J, Norgaard M, et al. Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis. Aliment Pharmacol Ther. 2006 Jul 1;24(1):111-6.; Камчатнов ПР, Умарова ХЯ, Чугунов АВ. Боль в спине: проблемы выбора адекватной терапии. Consilium medicum. Неврология и ревматология (Прил). 2015;(2):22-6. [Kamchatnov PR, Umarova KhYa, Chugunov AV. Back pain: the problem of choice of adequate therapy. Consilium medicum. Neurology and rheumatology (Suppl). 2015;(2):22-6. (In Russ.)].

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/687
https://doi.org/10.14412/1996-7012-2016-2-70-77

Кардіоваскулярна безпека як важливий критерій вибору нестероїдних протизапальних препаратів

Συγγραφείς: Golovach, I.Yu.

Πηγή: INTERNATIONAL NEUROLOGICAL JOURNAL; № 6.92 (2017); 68-74
МЕЖДУНАРОДНЫЙ НЕВРОЛОГИЧЕСКИЙ ЖУРНАЛ; № 6.92 (2017); 68-74
МІЖНАРОДНИЙ НЕВРОЛОГІЧНИЙ ЖУРНАЛ; № 6.92 (2017); 68-74

Θεματικοί όροι: нестероїдні протизапальні препарати, кардіоваскулярні ускладнення, ризик, напроксен, non-steroidal anti-inflammatory drugs, cardiovascular complications, risk, naproxen, нестероидные противовоспалительные препараты, кардиоваскулярные осложнения, риск

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://inj.zaslavsky.com.ua/article/view/111590

DYSLIPIDEMIA AND METABOLIC SYNDROME IN CHILDREN AND TEENAGERS AFTER THE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ; ДИСЛИПИДЕМИЯ И МЕТАБОЛИЧЕСКИЙ СИНДРОМ У ДЕТЕЙ И ПОДРОСТКОВ ПОСЛЕ АЛЛОГЕННОЙ ТРАНСПЛАНТАЦИИ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК

Συγγραφείς: N. V. Stancheva, E. V. Semenova, A. S. Borovkova, S. V. Razumova, P. V. Kozhokar, A. A. Rats, K. A. Ekushev, A. V. Kozlov, Yu. G. Phedyukova, O. V. Paina, A. Ya. Gudkova, L. S. Zubarovskaya, B. V. Afanasiev, Н. В. Станчева, Е. В. Семенова, А. С. Боровкова, С. В. Разумова, П. В. Кожокарь, А. А. Рац, К. А. Екушев, А. В. Козлов, Ю. Г. Федюкова, О. В. Паина, А. Я. Гудкова, Л. С. Зубаровская, Б. В. Афанасьев

Πηγή: Russian Journal of Pediatric Hematology and Oncology; Том 2, № 2 (2015); 43-49 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 2, № 2 (2015); 43-49 ; 2413-5496 ; 2311-1267 ; 10.17650/2311-1267-2015-2-2

Θεματικοί όροι: кардиоваскулярные осложнения, dyslipidemia, metabolic syndrome, cardiovascular complications, дислипидемия, метаболический синдром

Περιγραφή αρχείου: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/101/97; Zambetti M., Moliterni A., Materazzo C. et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001;19:37–43.; Tichelli A., Bucher C., Rovó A. et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 2007;110:3463–71.; Bhatia S., Francisco L., Carter A. et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007;110:3784–92.; Rackley C., Schultz K. R., Goldman F. D. et al. Cardiac manifestation of graft-versus-host disease. Biol Blood Marrow Transplant 2005;11(10):773–80.; Stancheva N., Semenova E., Borovkova A. et al. Structural changes of myocardium and state of RASS in children and adolescence after allogeneic hematopoietic stem cell transplantation. 38 Annual Meeting of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012;47(suppl 1):347.; Маркова И. В., Зубаровская Л. С., Козленок А. В. и др. Морфофункциональное состояние миокарда у детей после трансплантации аллогенных гемопоэтических стволовых клеток. Материалы Конгресса гематологов России, 2–4 июля 2012 г. Гематология и трансфузиология 2012;3:125. [Markova I. V., Zubarovskaya L. S., Kozlenok A. V. Morphofunctional state of the myocardium in children after transplantation of allogeneic hematopoietic stem cell. Materials of Congress Russian hematologists, 2–4 July 2012. Gematologiya i transfuziologiya = Hematology and Transfusiology 2012;3:125. (In Russ.)].; Annalaro C., Usardi P., Airaghi L. et al. Prevalence of metabolic syndrome in longterm survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant 2008;41:797–804.; Taskinen M., Saarinen-Pihkala U. M., Hovi L., Lipsanen-Nyman M. Impaired glucose tolerance and dislipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 2000;356:993–7.; Gregory J. W. Metabolic disorders. Endocr Dev 2009;15:59–76.; Baker K. S., Armenian S., Bhatia S. Long-term consequences of hematopoietic stem cell transplantation: Current state of the science. Biol Blood Marrow Transplant 2010;16(1 Suppl):S90–6.; Bajwa R., Skeens M., Garee A. et al. Metabolic syndrome and endocrine dysfunctions after HSCT in children. Pediatr Transplant 2012;16(8):872–8.; Rovó A., Tichelli A.; Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Cardiovascular complications in long-term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol 2012;49:25–34.; Васюкова О. В. Федеральные клинические рекомендации по диагностике и лечению ожирения у детей и подростков. М., 2013. [Vasyukova O. V. Federal guidelines for the diagnosis and treatment of obesity; in children and adolescents. M., 2013. (In Russ.)].; Zimmet P., Alberti G., Kaufman F. et al. The metabolic syndrome in children and adolescents: the IDF consensus. Diabetes Voice 2007;52(4):29–32.; Legault L., Bonny Y. Endocrine complications of bone marrow transplantation in children. Pediatr Transplant 1999;3:60–6.; Rovó A., Daikelter T., Halter J. et al. Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with HLA-identical sibling donor. Hematologica 2011;96:150–5.; Majhail N. S., Flowers M. E., Ness K. K. et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2009;43:49–54.; Туркина Т. И., Щербакова М. Ю. Особенности дислипидемий у детей. Рациональная фармакотерапия в кардиологии 2011;7(1):65–9. [Turkina T. I., Shcherbakova M. Yu. Dyslipidemia features; in children. Ratsionalʼnaya pharmakoterapiya v kardio logii = Rational Pharmacotherapy; in Cardiology 2011;7(1):65–9. (In Russ.)].; Vantyghem M., Cornillon J., Decanter C. et al.; Société Française de Thérapie Cellulaire. Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation. Orphanet J Rare Dis 2014;9:162.; https://journal.nodgo.org/jour/article/view/101

Διαθεσιμότητα: https://journal.nodgo.org/jour/article/view/101
https://doi.org/10.17650/2311-1267-2015-2-2-43-49

“CVCACS” MODEL FOR PREDICTION OF CARDIOVASCULAR COMPLICATIONS IN HOSPITALIZED PATIENTS WITH ACUTE CORONARY SYNDROME ; МОДЕЛЬ «CVCACS» ДЛЯ ПРОГНОЗИРОВАНИЯ РАЗВИТИЯ КАРДИОВАСКУЛЯРНЫХ ОСЛОЖНЕНИЙ В ГОСПИТАЛЬНОМ ПЕРИОДЕ ОСТРОГО КОРОНАРНОГО СИНДРОМА

Συγγραφείς: E. T. Manyukova, M. A. Shalenkova, Z. D. Mikhailova, Э. Т. Манюкова, М. А. Шаленкова, З. Д. Михайлова

Πηγή: Medical Immunology (Russia); Том 17, № 1 (2015); 81-86 ; Медицинская иммунология; Том 17, № 1 (2015); 81-86 ; 2313-741X ; 1563-0625 ; 10.15789/1563-0625-2015-1

Θεματικοί όροι: острый коронарный синдром, interleukin-10, highly sensitive C-reactive protein, cardiovascular complications, acute coronary syndrome, интерлейкин-10, высокочувствительный С-реактивный белок, кардиоваскулярные осложнения

Περιγραφή αρχείου: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/812/756; Ардашев В.Н., Калёнова И.Е., Ляпкова Н.Б., Потехин Н.П., Фурсов А.Н. Доказательная медицина: обзор современных математических методов анализа: Монография. М.: АВН, УНМЦ УД Президента РФ, 2013. 224 с. [Ardashev V.N., Kalyonova I.E., Lyapkova N.B., Potehin N.P., Fursov A.N. Evidence-based medicine: review of modern mathematical methods of analysis: Monograph]. Moscow: AVN, UNMC UD of the President of RF, 2013. 224 p.; Данько А.А., Белков С.А., Репетий Н.Г., Лысов А.Ю., Минкова Т.А., Матвеев А.А., Палченкова М.В. Цитокиновый профиль при сочетанном течении острого инфаркта миокарда с внебольничной пневмонией // Военно-медицинский журнал, 2012. Т. 333, No 11. С. 59-61. [Danko A.A., Belkov S.A., Repetiy N.G., Lyisov A.Yu., Minkova T.A., Matveev A.A., Palchenkova M.V. Cytokine profile during combined course of acute myocardial infarction with community-acquired pneumonia. Voenno-meditsinskiy zhurnal = Medical Corpse Journal, 2012, Vol. 333, no. 11, pp. 59-61. (In Russ.)]; Здравоохранение в России. 2013 г.: Стат. сб. / Росстат. М., 2013. 380 с. [Public health in Russia. 2013: Stat. sb./Rosstat]. Moscow, 2013. 380 p.; Карпов А.М., Рвачева А.В., Шогенова М.Х., Жетишева Р.А., Масенко В.П., Наумов В.Г. Современные представления об иммуновоспалительных механизмах атеросклероза // Атеросклероз и дислипидемии, 2014. Т. 14, No 1. С. 25-30. [Karpov A.M., Rvacheva A.V., Shogenova M.H., Zhetisheva R.A., Masenko V.P., Naumov V.G. Immunoinflammatory mechanisms of atherosclerosis: modern consepts. Ateroskleroz i dislipidemii = Journal of Atherosclerosis and Dyslipidaemias, 2014, Vol. 14, no. 1, pp. 25-30. (In Russ.)]; Комаров А.Л., Панченко Е.П. Роль воспаления в развитии атеротромбоза: “противовоспалительные” эффекты клопидогрела // Фарматека, 2007. Т. 143, No 8/9. С. 23-29. [Komarov A.L., Panchenko E.P. The role of inflammation in the course of atherothrombosis: “anti-inflammatory” effects of clopidogrel. Farmateka = Рharmateca, 2007, Vol. 143, no. 8/9, pp. 23-29. (In Russ.)]; Мохов А.А. Концепция развития системы здравоохранения в Российской Федерации до 2020 г. и ее правовое обеспечение // Российская юстиция, 2011. No 8. С. 48-50. [Mohov A.A. The conception of development of Public Health System in Russian federation till 2020 and its legal base. Rossiyskaya yustitsiya = Russian Justice, 2011, no. 8, pp. 48-50. (In Russ.)]; Оганов Р.Г. Национальные клинические рекомендации. Сборник. М.: Силицея-Полиграф, 2009. 528 с. [Oganov R.G. National clinical guideline. 4rd ed.]. Moscow: Silitseya-Poligraf, 2011. 568 p.; Оганов Р.Г., Масленникова Г.Я. Демографические тенденции в Российской Федерации: вклад болезней системы кровообращения // Международный журнал сердца и сосудистых заболеваний, 2013. Т. 1, No 1. С. 3-10. [Oganov R.G., Maslennikova G.Ya. Demographic trends in the Russian Federation: the impact of cardiovascular disease. Mezhdunarodnyy zhurnal serdtsa i sosudistykh zabolevaniy = International Journal of Heart and Vascular Diseases, 2013, Vol. 1, no. 1, pp. 3-10. (In Russ.)]; Рекомендации по лечению острого коронарного синдрома без стойкого подъёма сегмента ST/ Рабочая группа Европейского общества кардиологов // Рациональная Фармакотерапия в кардиологии, 2012. No 2 (приложение). С. 1-61. [Guidelines for the treatment of Non-ST-Segment Elevation Acute Coronary Syndrome/ Task group of European Society of Cardiology. Ratsional`naya Farmakoterapiya v kardiologii = Rationale for Drug Therapy of Cardiology, 2012, no. 2, рр. 1-61. (In Russ.)]; Шрейдер Е.В., Шахнович Р.М., Казначеева Е.И., Босых Е.Г., Ткачев Г.А, Руда М.Я. Прогностическое значение маркеров воспаления и NT-proBNP при различных вариантах лечения пациентов с острым коронарным синдромом // Кардиологический вестник, 2008. Т. III (XV), No 2. С. 44-53. [Shreider E.V., Shakhnovich R.M., Kaznacheyeva E.I., Bosykh E.G., Tkachev G.A., Ruda M.Ya. Prognostic value of inflammatory markers and NT-proBNP in different treatment options for patients with acute coronary syndrome. Kardiologicheskiy vestnik = Cardiological Bulletin, 2008, Vol. III (XV), no. 2, pp. 7-14. (In Russ.)]; Granger C.B., Goldberg R.J., Dabbous O.H., Pieper K.S., Eagle K.A., Cannon C.P., Van De Werf F., Avezum A., Goodman S.G., Flather M.D., Fox K.A. Predictors of hospital mortality in the global registry of acute coronary events. Arch. Intern. Med., 2003, Vol. 163, pp. 2345-2353.; Libby P. Okamoto Y., Rocha V., Folco E. Inflammation in atherosclerosis: transition from theory to practice. Cirс J., 2010, Vol. 74, pp. 213-220.; Mälarstig A., Eriksson P., Hamsten A., Lindahl B, Wallentin L., Siegbahn A. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart, 2008, no. 94, pp. 724-729.; https://www.mimmun.ru/mimmun/article/view/812

Διαθεσιμότητα: https://www.mimmun.ru/mimmun/article/view/812
https://doi.org/10.15789/1563-0625-2015-1-81-86